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ADP Adenosine diphosphate 
cAMP Cyclic adenosine Monophosphate 
ATP Adenosine triphosphate 
d Day(s) 
DMF AyV-Dimethyl formamide 
DMSO Dimethyl sulfoxide 
EP Prostaglandin endoperoxide 
Et Ethyl 
g : Gram(s) 
h Hour(s) 
HO Ac Acetic Acid 
FVP Flash vacuum pyrolysis 





N.M.R. Nuclear Magnetic Resonance 
PG Prostaglandin 
PGEi Prostaglandin Ej 
PGF1 a Prostaglandin F \ ^  
PGI2 Prostacyclin (PGX) 
Ph Phenyl 
PPA Polyphosphoric acid 
PPE Polyphosphate ester 
r.t. Room temperature 
TFA Trifluoroacetic acid 
THF Tetrahydrofiiran 
TLC Thin layer chromatography 
TP-receptor : Thromboxane receptor 
TTFA Thallated trifluoroacetic acid 
TXA2 Thromboxane A � 
ii 
Definition 
Full Agonists : 
They elicit a maximum response (A below) whilst occuping only a small 
proportion of the total number of receptors on the cell (e.g. prostacyclin 
(6), iloprost (7) and cicaprost (8) on IP-receptors). 
100 
Response (%) J 
0 ~ — — 
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Partial Agonists : 
They cannot produce a maximum response (B above) even occupying 
almost all the receptor sites (e.g. octiinibate (13) on IP-receptors). 
Antagonists : 
They bind to receptor but do not elicit any response, and prevent the 
access of the agonists to receptor sites. This phenomenum is often called 
competitive reversible antagonism. Antagonists (Antag) move the dose-
response curve of the agonists to the right as shown below. 
Response (%) / / A with 
/ / antag 
0 J — 
-9 -8 -7 -6 




Prostacyclin (PGI2) (6) was found to be the most potent 
inhibitor of platelet aggregation. It acts on IP-receptor for agonists activity. 
Up to now, no antagonists of IP-receptor have been developed, although 
partial agonists such as octimibate (13) has been identified. In this thesis, 
non-prostanoid compounds (20, 27, 33, 38, 43, 50, 53, 57, 60, 64，and 
66) of structure similar to octimibate (13) was prepared and their activities 
was tested. (27) is the most potent platelet aggregation inhibitor 
synthesized in this study with IC50 of 12.2 jiiM. The results so far show 
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I. Introduction - Discoveries and Background 
Prostaglandins (PGs) were discovered in the early 1930's by von 
Euler and coworkers in Sweden^ and found to have both smooth muscle 
stimulating and vasodepressor activities^. Later, Bergstrom and coworkers 
unveiled that the prostaglandins are carboxylic acids with a 20-carbon 
structure including a 5-membered ring. They may be considered as 
derivatives of prostanoic acid3,4 (1). 
(1) 
The prostanglandin-synthesizing enzymes are distributed widely 
in animal tissues5，6. Hence, almost every tissue of the body contains small to 
moderate amounts of prostaglandins. These substances are released into the 
local tissue fluids and into the circulating blood under physiological and 
pathological conditions. Although some of the prostaglandins cause 
vasoconstriction, most of the more important ones seem to be mainly 
vasodilating agents?. 
During the summer of 1975, Moncada and Vane isolated an 
enzyme in platelet microsomes responsible for the biosynthesis of 
thromboxane A? (TXA2) (2) from prostaglandin endoperoxides^ and called it 
thromboxane synthetase '^^ . 
,lO 广 u 
OH 
(2) 
T X A j is a potent inducer of platelet aggregation and a profound constrictor of 
vascular smooth muscle. Later, they carried out investigations in collaboration 
with Gryglewski and Bunting, to demonstrate if tissues other than platelets 
contain thromboxane synthetase. They began with vascular tissues and were 
disappointed to find that TXA2 was not formed. But the cascade bioassay 
technique 10 indicated that the endoperoxide precursor in microsomal fractions 
of blood vessels was consumed enzymatically into an unknown product 
which relaxed the celiac and mesenteric arteries of the rabbit. They called this 
unknown product PGXU. They thought that the vessel walls of vascular 
tissues might synthesize a biological opposite of TXA�，as a defense 
mechanism against platelet aggregation and showed that PGX was the most 
potent inhibitor of platelet aggregation yet discovered (IC50 = 1.02 r|M). It 
inhibits platelet aggregation by stimulating adenylate cyclase, leading to an 
increase in cAMP (cyclic adenosine monophosphate) levels in platelets^^js 
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Figure 1 : Mechanism of the Inhibitory Action of PGI. on Human Platelets 
2 
(PGEi)i4 (3) and more than 1000 times more active than adenosine15 (4). 
o 
八 . � 2H V ^ l / � O H 
恥 OH OH OH 
(3) (4) 
PGX is not only more potent in elevating cAMP, but also has a prolonged 
effect. It also increases cAMP in cells other than platelets, for instance, 
human fibroblasts^^ and human fat cell ghostsi?. Vargaftig and Chignardi^ 
demonstrated that PGEi by increasing cAMP in platelets inhibits the release 
of TXA2 in platelets. Hence, it is possible that an interaction between the 
PGX and TXA2 system exerts an overall control of platelet aggregability in 
vivo. Hopkins and Goraiani^ reported that PGX increases cAMP in the 
endothelial cells and hence results in a negative feedback control for PGX 
production by the endothelial cells. 
Later work showed that PGX was also a potent relaxant of 
c o r o n a r y 2 0 and splanchnic vascular strips in vHw!�and a potent vasodilator 
in v/w22,23 In addition, PGX had strong antithrombotic activity in v/w?24，25 
PGX was the major metabolite of arachidonic acid in vascular 
tissue26，27. It is chemically unstable however, forming 6-0x0 PGFia in neutral 















Figure 2 : The Metabolic Pathway of Arachidonic Acid 
4 
The structure ofPGX was established in 1976 in a collaboration 
between scientists from the Wellcome Research Laboratories and the Upjohn 
C o m p a n y 2 6 . Then PGX was renamed prostacyclin with the abbreviation of 







Although prostacyclin is commerically available (its trade names 
are Flolan (Wellcome) and Cyclo-prostin (Upjohn)), its utility is limited by its 
chemical instability. This is due to the extreme instability of the enol ether 
function which is subject to intramolecularly-catalyzed hydrolytic 
decomposi t ion29，30 its half-life of decomposition is about 2 to 4 min under 
physiological conditions. Its activity disappears within 15 sec in boiling water 
at neutral pH and within 10 min at TTC and at neutral pH. However, alkaline 
d H increases 
the stability of prostacyclin ( ty�=100 hr at pH 10.5 & 2 5 � C P . 
Many pharmaceutical chemists tried to overcome instabilty due 
to the enol ether moiety of prostacyclin. Early development of analogs of 
prostacyclin focused upon modifying and stablizing the labile enol ether 
5 
functionality. Iloprost32 (7), cicaprost^ ^ (8), beraprost^ ^ (9), and taprostene^^ 




Hd OH OH 
(7) (8) 
COOH 
> h o o c h O 
rb K 
CH3 .CH3 ^ 广 
HO 5H 8H 
(9) (10) 
The studies of Armstrong and coworkers奶 on thromboxane 
receptor antagonists revealed that prostaglandin endoperoxide analogs with a 
diphenyl methoximino side chain such as EP035 (11) and EP157 (12) 
exhibited both thromboxane receptor blocking activity (i.e. TP-receptor 
antagonism) and agonist activity at prostacyclin receptors (i.e. IP-receptor 
agonists). This was strange since the that EP analogs were far removed from 
the previously developed structure-activity relationships of prostacyclin 
analogs. It was further noted that EP035 (11) and EP157 (12) appeared to be 
6 
filll agonists with respect to inhibition of aggregation and to activation of 
adenylate cyclase in human platelets. 
XOOH COOH 
r T Y ' i T ^ i f ^ , 
(11) (12) 
Meanwell, Merritt and their coworkers]? have recently 
demonstrated that the triphenylated imidazole derivative, octimibate, (8-
[(1,4,5-triphenyl-1 //-imidazol-2-yl)oxy]octanoic acid) (13) inhibits platelet 
function by binding to the platelet PGI2 receptor and stimulating adenylate 
cyclase. However, octiinibate does not maximally activate the adenylate 
cyclase system. It has been suggested that octimibate is a partial agonist at 
the prostacyclin receptor (IC50 三 10 r|M for inhibition of aggregation induced 
by several different agonists, including U46619 ( 1 ^ I M ) and A D P (20 |liM); 
IC50 = ItiM for iloprost). Since partial agonists are potential lead compounds 
to true antagonists, the study of the structure of octimibate could be helpful 




From a chemical standpoint, octimibate analogs are less complex 
and structurally different from PGI2 and its close analogs. Moreover, they 
lack the inherent stereochemistry of the bicyclic EP analogs. Hence, 
development of octimbate analogs as prostacyclin receptor antagonists is 
attractive and this type of agent could be useful in assessing the roles of PGI2 
and PGE2 in inflammation. 
At present, there are no reports of the existence of prostacyclin 
receptor antagonists. However, during the course of our research, Meanwell 
and coworkers38-40 have reported some partial agonists at prostacyclin 
receptor which are either triphenylated pyrazole derivatives, diphenylated 
pyrazole and oxazole derivatives related to octimibate. The most potent 
inhibitors in their studies were 3,4,5-triphenyl-l//-pyrazole-1 -nonanoic (IC50 
=0.4 (14), c/5-[3-[2-(4,5-diphenyl-2-oxazolyl)ethenyl]phenoxy]acetic 
(14) 




oxazolyl)ethyl]phenoxy]acetic acid (IC50 = 0.34[iM)4() (16). 
O^COOH 
(16) 
All of these compounds possess heterocyclic rings with aryl 
substituents and an alkanoic acid chain. They therefore serve as our lead 
compounds for the development of prostacyclin receptor antagonists. 
II. Our Approach 
Our approach was to synthesize a series of compounds similar in 
structure to octimibate by modifying its central heterocyclic ring of octimibate 
(i.e. the imidazole ring). We have replaced the imidazole ring with oxazole 
(A), benzoxazole (B), triazole (C), fiiran (D), benzofuran (E), indole (F), and 
benzene (G) ring; or there is no ring (H) (Figure 3). 
9 
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Figure 3 : The Replacement of Imidazole Ring with Other Ring Systems 
Brief reviews of the known methods for synthesizing these ring 
systems are given below. 
A. Oxazole ring 
Oxazolone : 
a-Benzoylaminocarboxylic acids which are prepared by 
benzoylation of the corresponding amino acids, are cyclized by using iV-ethyl-
jV-(Y-dimethylaininopropyl) carbodiimide hydrochloride's to give 5(4//)-
oxazolones. 
10 
O R R 
X 丄 （-H2()) V - N 
Ph 八 nAcOOH ^ ^ 
Other commonly used dehydrating agents are acetic anhydride and sodium 
acetate^i, acetic anhydride and lead acetate", polyphosphoric acid^ ,^ sulfiir 
trioxide / dimethyl formamide complex44, perchloric acid45，46 and 
carbodiimide47,48 
Huang and his coworkeH^ have prepared A^-acyl-a-amino acids 
by reaction of the corresponding amino acids with A^-acylthiazolidine-2-
thiones. 5(4//)-Oxazolones are thus formed by the reaction of the protected 
amino acids with cyanuric chloride in the presence of triethylamine. 
R, ？ O R , 
A II T 
H 力人 COOH + RCONyS ^ R 八 JJ 八 COOH 
CICN 貪 ^ N 
— 乂 乂 R 
Chen and his coworkers^^ have used ClCOsMe as condensation 
reagent in the presence of A^-methylmorpholine to form optical active 5(4//)-
oxazolones with enantiomeric excess of 83-98 %. 
o R' ^ V - N 
Jl 丄 ClCOOMe i 




Two comprehensive reviews on oxazole chemistry have been 
published by Comth^i and by W i l e y 5 2 . These two reviews have covered all 
literatures up to 1955. Newer methods and modifications of older methods for 
preparing oxazoles have been mentioned by Turchi and Dewar53 in 1974. In 
the same year, Lakhan and Temai^ ^ have published a review on advances in 
oxazole chemistry. 
Generally, a-acylaminocarbonyl compounds are cyclized to give 
2,4,5-trisubstituted oxazoles by employing different dehydrating agents such 
as sulfuric acid55，phosphorus pentachloride^^, phosphorus oxychloride^^, 
phosphorus pentoxide^^, thionyl cliloride^ ,^ a mixture of acetic anhydride and 
concentrated sulfuric acid60, 98 % phosphoric acid in acetic anhydride^i, and 
anhydrous hydrogen fluoride^^ 
R； ^H R'v 
The major problem in such synthesis is the difficulty in obtaining 
the starting material - a-acylaminocarbonyl compounds. Balaban and 
c o w o r k e r s 6 3 have developed a method for the synthesis of these compounds. 
A^-acylamino acids are cyclized to give azlactones which react with aromatic 
hydrocarbons in the presence of A I C I 3 under Friedel-Crafts conditions to give 
a-acylaminocarbonyl compounds. 
« 0 ^ : “ . ^ ^ A 答 . 
12 
Blumlein64 and Lewy^^ have prepared 2,4-disubstituted oxazoles 
by reacting a-bromo ketones with amides. This method is also applicable to 
the preparation of trisubstituted oxazoles. Marquez^^ have prepared several 4-
phenyl-2,5-disubstituted oxazoles by using a similar strategy. 
Ph^ .O P h 、 . O Ph、 
Br2 丫 R'C0NH2 ^ N 
R ^ ^ R ^ B r 
Davidson and his c o w o r k e r s 6 7 have reported that acyl 
derivatives of benzoin react with ammonium acetate in glacial acetic acid to 
give 2-substituted 4,5-diphenyloxazoles. 
R � ^ o R�^NH, R \_N 
丫 o NH40AC • Y ? (-H20) , 
R.^^O 入 R,, HOAc r,^^^o-^RH 八 R" 
2-Substituted or 2-unsubstituted 4,5-diphenyloxazoles are 
prepared by the reaction between benzoin and nitrile or hydrogen cyanide^ .^ 
p 丫 _ C N 貧 p Y > ^ y ^ 
Ph 人 OH H+ Ph-^O-^R(H) P h � 入 R 冊 
a-Hydroxyimino ketones react with aldehydes in the presence of 
dry hydrogen chloride to form oxazole TV-oxides which are reduced with zinc 
in acetic acid to give oxazoles. This reaction had been first described by Diels 
and Riley^9, and was later extended by Dilthey^o, Selwitz^i and their 
13 
coworkers. Weintraub72 has used aliphatic aldehydes instead of aromtic 
aldehydes for the synthesis of trisubstituted oxazoles. 
© 
R ^ N O H P R v 
^ R"CHO ^ 广 1 Zn/HOAc • / f ~ \ 
R •入 O HCl/HOAc 入 R., ^ R ^ ^ 人 R" 
The reaction between a-halo ketones with sodium salt of anti-
benzaldoxime or between iV-hydroxy-a-amino ketones with aldehydes forms 
A^-(aroylalkyl) nitrones, which are cyclized in acetic anhydride-sulfiiric acid to 
give oxazoles73. 
Ar. .O 0 • 
, PhCH=N-ONa > 
E t O H / l O C 
R Br Ar O R 
T ^ AC20/H2SO4 ^ 
R N ^ P h 
Ar. I 
�� FhCHO O 
八 E t O H / r t ^ 
R NHOH 
Nitrile-SnCl4 complex reacts with substituted desyl chlorides to 
afford nitrilium salts, which cyclize smoothly to give 2,4-disubstituted 5-
phenyloxazoles74. 
P h ^ O P h ^ O \ N 
丫 RCN/SnCl4 J ^ J i 
R 人 a R人 ? J式R ’ P h 八 入 R , 
Zbiral and his coworkers?，have reported that the reaction of 
acyl chloride with a-azido ketones or a-azido esters in the presence of 
14 
triphenylphosphine also gives oxazoles. 
R S ^ o V N 
T " � X > J - , 
R 人 N3 PhjP/PhH 八 R" 
Recently, Cunico and his coworker?^ have shown that O-
trimethylsilyl acylsilane cyanohydrins can be employed for the formation of 
oxazoles. 
OTMS ？Ac 
T 1. ^ FVPor ^ 
R 言IMS 2. Ac20 : IMSOTf R 人 入 Me 
B. Benzoxazole Ring 
2-Aininophenol and carboxylic acids are cyclized in 
polyphosphate ester (PPE) to form benoxazoles??. 
OC + ^^ 
Similarly, 2-aminophenol and oxime are cyclized in a refluxing 
benzene-ether mixture to give benzoxazole '^^ . 
O："^  + Be 一 ， 
^^-^OH CI ^ ^ 
15 
When 1,2,4-benzoxadiazines are heated in chlorobenzene at 
reflux under nitrogen, benzoxazole are formed through the thermal extrusion 
ofnitrene ( N H ) 7 9 . The nitrene is then converted to ammonia and nitrogen. 
^ O O ^ R + 細 2 + 1/3NH3 
C. Triazole Ring 
Ethyl benzoate is converted to acid hydrazide by treatment with 
hydrazine hydrate^ .^ Semicarbazide is prepared by treatment of the acid 
hydrazine with phenyl isocyanate^i. Condensation and cyclization of the 
semicarbazide by refluxing with IN sodium hydroxide aqueous solution give 
triazolone82. 
N2H4 H2O ‘ V R'NCQ ‘ 
RCOOEt — • R - C NH NH, S l ^ ^ 
H 
N-N 
？\ I? INNaOH _ 议人 X 
R-C-NH-NH-C-NH-R ' • ^ N O 
I 
R, 
D a v i d s o n 8 3 has reported another method for synthesizing 
triazolones. Sulfiiration of TV-arylated arylamide with phosphorous 
pentasulfide gives thiobenzanilides, which is condensed with hydrazine to 
give A^-arylbenzamidrazones. Treatment of A^-arylbenzamidrazones with 
(PhO)2CO would yield the triazolones. 
16 
N - / 
« 丄 <PHO,CO • R 乂 人 
知 k’ 
Similarly, reaction of TV -^substituted amidrazones with COCI2 
also gives triazolone^^. 
H 
N-NH2 N-N 
R J COCI2 乂 X 
NH ^ K \N O 
I I 
R' R, 
PhCCl3 reacts with PhNHCSNHNH� in EtOH to give 
EtOCPh:NNHCONHPh which in turn undergoes thermolysis to give 
triazolone85. 
O PhCCl3 o Ph 






D. Furan Ring 
The synthesis of 3,4-disubstituted fiirans is a difficult task since 
ftiran derivatives tend to undergo both lithiation and electrophilic substitution 
17 
at C-2 and C-5 positions^ .^ Elaborate methods to overcome these problems 
have been developed. These include intermolecular Diels-Alder reaction and 
preparation ot furan ring from acyclic precursors. 
3,4-Diphenylfiiran was prepared by a Diels-Alder reaction of 4-
phenyloxazole and diphenylacetylene in the presence of triethylamine in a 
sealed-tube according to the procedure of Ho and Wong87 
Ph Ph Vh 
+ Ph Ph ——^ • 
V (-PhCN) V 
Konig and his coworkers^^ have reported that the thermal 
reaction of 4-methyloxazole instead of 4-phenyloxazole, and 
diphenylacetylene at 200 °C gives the same furan in 89 % yield. 
Me P h ^ ^ ^ P h 
X j + Ph — P h Q 
Thermolysis of c/5-cyclobutenediols by refluxing with 4-Me-
C6H4SO3H or H 3 P O 4 gives tetrasubstituted fiirans^^. 
R R K R 
‘MePhSOjHor 、~~{ 
H 3 P O 4 r . / ^ X R . 
OHOH 
The dehydrogenation of 3,4-diphenyltetrahyclrofiiran might 
provide an alternative route to 3,4-diphenylfuran. The tetrahydrofuran was 
18 
obtained by acid-catalyzed cyclization of 2,3-diphenylbutane-l ,4-diol with 
continuous removal of water. Pyrolysis of the tetrahydrofiiran with elemental 
sulfiir eventually furnishes a fiiran nucleus^ .^ 
Ph Ph 
MeOOC^O^COOMe + W _ N a U M e _ ^ 
MeOH 
Ph� Ph / h 
Y i 肌 • O 
HOOC ^ ^ 
Okazaki and coworkers^^ have prepared 3,4-disubstituted furans 
by the reaction of a-oxo ketene dithioacetals with dimethylsulfonium 
methylide. The reaction of a-oxo ketene dithioacetals with dimethylsulfonium 
methylide afforded dihydrofurans which was converted into furans readily by 
one of several methods, e.g. (i) treatment with catalytic aqueous HCl, (ii) 
chromatography on Florisil column, or (iii) treatment with methyl iodide in 
aqueous acetone, followed by catalytic reduction with Raney Ni. 
R R' R � R' \ / 
H • 側 e ^ ^ ——^ G s M e 
I o SMe 
SMe 
R R' 
Recently, Song and Wong^ ^ have reported a convenient 
synthesis of 3,4-disubstituted fiiran from 3,4-bis(trimethylsilyI)fiiran through 
19 
boroxine intermediates. 3,4-Bis(trimethylsilyl)fiiran can be converted 
regiospecifically into various boroxines, which can then undergo the Suzuki-
type cross-coupling reactions to give 3,4-disubstituted furans. 
V - N Me3Si SiMcj 
O + SiMe3 二义 -
1. BCI3, CH2CI2 ^ ^ ^ B Z O � B J ^ ME3SI R 
• i � A RX,[Pd(PPh3)4| V Y 
2. 5 % A Q . H C I / ME3SI 丫 I M ^ ^ N I ^ C O J ^ 1 } 
lMaq.Na2C03 l ^ s i M c j MeOH-PhMe ^ 
1. B C U , C H I C H ^ S ^ ® ^ R' R 
0°C 2 2 T 6 � i R'X,[Pd(PPh3)4]^  Y y 
2. lMNa2C03 ^ ？ IMaq.NazCOj [ X 
JV. R M E O H - P H M E � 
E. Benzofuran Ring 
The reaction of cuprous acetylide with bromophenol has been 
proved to be an efficient pathway for the synthesis of benzofuran^ .^ 
P C o H + 一 = , ( 0 0 - H 
Recently，Hundu and his coworkers^^ have reported that 2-
iodophenol reacts with acetylenes in the presence of Pd(PPh3)2Cl2 or 
Pd(OAc)2 catalyst and triethylamine to give benzofurans. 
20 
O C o H + HC 式《 
Palladium-promoted cyclization of O-allylic or vinylic phenols to 
2- and 3-substituted benzofurans, respectively has been found to be another 
successful route96. 
o c ^ ^ 
Ph 
a ； ^ ^ 0:5 
Ph 
2-Substituted fiirans are usually prepared by the palladium 
catalyzed cross-coupling of 2-trimethylstannyl-resorcinoltricarbonyl 
chromium (0) complexes and the corrsponding 2 - h a l o - b e n z o f i i r a n s 9 7 . 
(Me)3Sn 
备 I + 
OSi(Me)2^-Bu 
THF 广-BuPh^SiO^^"^^^"^^ ^ \ 
OSi(Me)2^-Bu 
21 
Photocyclization of benzoin acetate in solid cyclodextrin (CD) 
complexes gives selectively the type-2 product, i.e. 2-phenylbenzofiiran, 
along with less than 1 % of the other type-1 products^ .^ 
OAc OAc 




TyP® 2 ph-CH-CH-Ph 
^ ^ ^ ^ ^ OAc OAc 
OAc OAc o 
( g r V ^ ^ O ^ • 广 — — ^ 
PhCHO 
Reaction of 2'-bromodeoxybenzoin with activated bronze in 
refluxing dimethylacetamide fiimishes 2-phenylbeiizofiiran via radical 
cyclization process^ .^ 
你 CH^COPh 少 1】 CHzCOPh 
l y i ^ B r • p . + Br-
CutlJ CulO] 
O O ^ ^ ^ + H+ 
22 
Intromolecular reductive deoxygenation of O-
aryloxyacetophenones using titanium (IV) chloride and zinc has been found to 
be another means to form b e n z o f i i r a n s i o o . 
l O i 
Me 
Me 
F. Indole Ring 
An important method for the preparation of substituted indoles, 
known as the Fischer indole synthesis, includes heating the phenylhydrazone 
of an aromatic aldehyde, ketone or keto acid in the presence of an acid 
catalyst, such as zinc chloride, hydrochloric acid, acetic acid and 
polyphosphoric acid (PPA). 
A one pot synthesis of 2-phenylindole by the anhydrous reaction 
of acetophenone and phenylhydrazine under microwave irradiation has been 
reported by Didier and coworkersloi. 
+ phNHNH2 Microwave ^ ^ ^ P h 
Barker and c o w o r k e r s i o 2 has reported that flash-pyrolysis of the 
vinylbenzotriazole at 600�C/10 - 2 torr gives the indole in 67 % yield. 
23 
Although vinylbenzotriazoles are easily available by a variety of routes, side 
reactions of the intermediate diradical always impose limitations and hence 
lead to a diminution of yields. 
“ ^ 吟 R 
Moreover, Plutitskii and coworkers^^^ have synthesized the 
indole by a thermal indolization of the phenylhydrazone, which is catalyzed 
by bases. 
/—\ NNHPh / P ^ ~ i 
O K • y r L p , 
^ ~ ^ Me fl 
Another route to the indole is carried out by a catalytic 
deoxygenation of the nitrostyrene by carbon monoxide using Ru3(CO)i2 as 
catalysti04. 
CO 、 射 R. + + � 2 
catalyst ^ ^ ^ ^ ^ M l f 
A convenient synthesis of the indoles from anilines has been 
disclosed by Taylori05. Thus, treatment of anilines with TTFA in a mixture of 
24 
TFA and ether leads to the regiospecific or//jo-thallated anilines. The ortho-
thallated anilines then react with the copper (I) salt of phenylacetylene in 
acetonitrile to form the 2-acetamidotolanes. Reaction of the 2-
acetamidotolane with palladium (II) chloride in acetonitrile gives l-acyl-2-
phenylindoles, from which indoles are prepared by deacylation with alcoholic 
potassium hydroxide. 
付 扉 C0CF3)2 一 h 嗎 ^ 
队 N H C O R , M e C N ， 8 1 C , 狄 • 隱 MeCN, 8 r c 
COR' 
Furthermore, Bischler's methodi06 has been employed for the 
synthesis of 2-phenylindoles. It has been found that primary aromatic amines 
react with (a-bromoacyl)-benzenes to fiimish indoles. 
Phenacyldimethylsulphonium bromide, which is prepared by 
reaction of phenacylbromide with dimethylsulfide, is converted to 2-
phenylindole in a mixture of aniline and A^/Z-diethylaniline. 
Phenacylidinedimethylsulphurane, formed by reacting phenacyldimethyl-











In addition to the modifications of the central ring, we could also 
modify the alkanoic acid chain. However, during the course of our studies, 
the structure-activity studies performed by Meanwell and coworkers)"。，o n 
the pyrazole and oxazole derivatives have demonstrated that the nonanoic 
acid side chain is the optimal length. Its homologs with one-carbon increment 
or reduction would cause a ten-fold reduction in potency. Any further change 
of the chain length results in a significant decrease in activities (Table 1). 
Table 1 : The Effect of the Change of Carboxylic Acid Chain Length to 
Activities of the Compounds 
R i y N � 
N—(CH2)nC02H 
R3 
^ n IC5o,^ M 
S Ph Ph 5 
Ph Ph Ph 6 22.4 
Ph Ph Ph 7 3.4 
Ph Ph Ph 8 0.4 
Ph Ph Ph 9 5.5 
Ph Ph Ph 10 18.6 
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Besides, any carboxylic acid derivative, such as ester, amide, N-
substituted amide, cyanide or tetrazole, is not as best as the carboxylic acid 
head. The results show that the methyl ester is ten-fold less potent than the 
corresponding acid. Primary amide is 100-fold less active. TV-Substituted 
amide and cyanide derivatives are inactive. In addition, tetrazole is only 2.5-
fold weaker than the corresponding acid^ 8-4o (Table 2). 
Table 2 : The Effect of the Change of Acid Derivatives to the Activities of the 
Compounds 
N-R 
P h 叫 
Ph 







Replacement of a carbon atom in the chain by oxygen atom at 
the p-position to carboxylate terminus causes little change in activity, while a 
sulfur atom at this position causes a two-fold reduction in potency. An 
increment in the oxidation state of sulfur to those of sulfoxide or sulfone 
results in further diminution in activity38"40 (Table 3). 
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Table 3 ： The Effect of the Change of Carbon to Other Heteroatoms on the 
Activities of the Compounds 
N-R 
P h 叫 
Ph 






The results of Meanwell and coworkers38-40, also show that 
replacement of the second phenyl ring of pyrazole derivatives with a benzyl 
or an ether group give inactive compounds (Table 4). 
Table 4 : The Effect of the Change of Substituents on the Activities of the 
Compounds 
R i \ ^ N � 
N—(CH2)nC02H 
R3 
Rl R2 R3 n IC5O,^ M 
？ii PhCH2 Ph 8 ^ 
Ph C2H5 Ph 8 >79 
From all of these results above, we have chosen octaiioic acid 
chain as our carboxylic acid chain. 
28 
111. Results and Discussion - Synthetic Strategy 
A. Oxazoie Derivatives 
I. a-Benzoylaminocarboxylic acids [17a : R = Ph, 17b : R = 
(CH3)2CH] which were prepared by benzoylation of the corresponding amino 
acids 108, were cyclized by using A^-ethyl-A/'-CY-dimethylaminopropyl) 
carbodiimide hydrochloride to give 5(4//)-oxazoIones [18a : R 二 Ph, 18b : R 
=(CH3)2CH]. We have chosen 7V-ethyk/V-(丫-dimethylaminopropyl) 
carbodiimide hydrochloride as the cyclo-dehydrating agent because the 
corresponding water-soluble urea salt formed after reaction was easily 
removable's. Alkylation of the oxazolones (18) with methyl 8-
bromooctanoate furnished esters (19) and subsequent saponification gave 
acids (20) (Scheme 1). 
NH2 NaOH • I 請 h 
R 人 COOH Phcoa R 人 COOH 
17a: 93 % 
17b: 86 % 
Ph 
CH3CH2N=C=N(CH2)3N(CH3)2 ^ l .NaH/DMF ^ 
CH2CI2 ^ N ^ W o 2.Br(CH2)7COOMe 
R 
18a: 96 % 
18b : 79 % 
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Ph 
^ ^ O ^ ^ ^ ^ ^ ^ ^ / ^ C O O M e NaOH/MeOH 於 
R 
19a: 4 5 % 
19b : 48 % 
Ph. 
20a: 83 % 
20b : 92 % 
(Scheme 1) 
II. Benzoin ester (21) was prepared by reacting benzoin with acetyl 
chloride. The acetyl derivative of benzoin (21) was then allowed to react with 
ammonium acetate in glacial acetic acid to give 2-methyl-4,5-diphenyIoxazole 
(22). Compound (22) was brominated with 7V-bromosuccinimide in the 
presence of benzoyl peroxide as catalysti09 to form 2-bromomethyl-4,5-
diphenyloxazole (23). The bromine atom was then replaced by a nucleophilic 
substitution with potassium acetate in an aprotic dipolar solvent such as 
DMF, affording 2-acetoxymethyl-4,5-diphenyloxazole (24). Saponification of 
the ester (24) under basic condition generated 2-hydroxymethyl-4,5-
diphenyloxazole (25) (Scheme 2). 
o l o 
MeCOCI 貪 N H 4 0 A C / H Q A C ^ 
S T ) Q T ^ ^ - 料 、 
30 
O l 
NBS/CCI4 _ MeCOOK/DMF 
( Q T (88 %) p r 
22 23 
0 L . a . 
_ K2C03/Me0H _ 
~ ( 9 7 %) j ^ ^ j ^ ^ ^ ' i O H 
24 25 
(Scheme 2) 
Alcohol (25) which was first reported by Aldous and coworkers ho in 1960, 
was also prepared by hydrolysis of bromide (23) in an aqueous alcohol 
solution of silver nitrate (Scheme 3). 
O l O k ^ N 
AgNCyEtOH 難 
^ O ^ O ^ B r (62 % ) I ^ J ^ OH 
^ 23 25 
(Scheme 3) 
However, Aldous and coworkers did not report the yield of the alcohol (25). 
When we repeated their procedure, only about 60 % yield of the alcohol (25) 
was isolated. Hence, we used our present method. Alkylation of alcohol (25) 
with methyl 8-bromooctanoate formed ester (26), and saponification gave 
acid (27) (Scheme 4). 
31 
O l 
⑶ 、 l .NaH/DMF _ 
2.Br(CH2)7COOMe ~ 






B. Benzoxazole Derivative 
2-Aminophenol and 4-methylbenzoic acid were cyclized in 
polyphosphoric acid (PPA)ii4 to form 2-(4-methylphenyl)benzoxazole (28). 
Using the same procedures in the preparation of 2-hydroxymethyl-4,5-
diphenyloxazole (25), the benzoxazole (28) was converted into 2-(4-
hydroxymethylphenyl)benoxazole (31) in three steps. Alkylation of alcohol 
(31) with methyl 8-bromooctanoate furnished ester (32), and saponification 
gave acid (33) (Scheme 5). 
32 
O C + H 5 > - M e _ _ ？ ^ ^ 
H ( / (85 % ) 
28 (78 % ) 29 
MeCOOK / DMF K z C X y M e O H 》 
30 
l .NaH/DMF ‘ 
i:JJ<c/ ~2.Br(CH2>7COOMe 
31 (56 % ) 
32 




C. Triazole Derivative 
Acid hydrazide (34) which was prepared by the reaction of 
benzoyl chloride and hydrazine hydrate^o, was converted to semicarbazide 
33 
( 3 5 ) upon treatment with phenyl isocyanate8�Condensation and cyclization 
of the semicarbazide (35) by refluxing with IN sodium hydroxide aqueous 
solution gave triazolone82 (36). Alkylation of the triazolone with methyl 8-
bromooctanoate fiimished ester (37), and saponification gave acid (38) 
(Scheme 6). 
N2H4.H2O PhNCO 
Et,0 T Me2CO 
COCI 2 CONHNH, 
(96 %) (80 %) 
34 
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(37 %) A 
^ ^ 37 
N-N 
NaOH/MeOH^ / ^ T ^ N 夂 





D. Furan Derivative 
3,4-Diphenylfuran (39) was prepared by Diels-Alder reaction 
and cycloreversion of 4-phenyloxazole and diphenylacetylene in the presence 
oftriethylamine in a sealed-tube^ .^ Formylation of furan (39) was achieved by 
reaction with ClCHOMe (from dichloromethyl methyl ether/titanium (IV) 
chloride) to give aldehyde (40) . Reduction of the aldehyde (40) with NaBH* 
flimished alcohol (41) Alkylation of the alcohol with methyl 8-
bromooctanoate ftimished ester (42), and finally saponification gave acid (43) 
(Scheme 7). 
Ph Ph Ph 
i + Ph 一 Ph — ^ — • / i 
S ) 乂 ( P h C N ) 
(71 %) 39 
1. CI2CHOCH3 Ph Ph Ph Ph 
TiCl4/CH2Cl2 W NaBH4/MeOH W 
— ~ ~ • 2NNaOH ^ i V ^ O H 
2.H2O V ^ C H O 
(86 %) � ” 
40 41 
Ph Ph 
LNaH /DMF > 







E. Benzofuran Derivative 
Swem oxidation^ of alcohol (25) with DMSO / oxalyl chloride 
gave 4,5-diphenyloxazole-2-carboxaldehyde (44) (Scheme 8). 
O L N 1.DMS0/CH2CI2 [ Q 1 N 
2. C0CI2 ^ ^ ^ ^ ^ 
P (92 %) 
25 44 
(Scheme 8) 
All attempts to prepare this aldehyde from bromide (23) under Sommelet 
conditionsu2 were met with unexpected complications. In these endeavors, 
only 40 % yield of aldehyde (44) was isolated along with other unidentified 
products (Scheme 9). 
O L I n 
^ ^ ^ ^ ^ V ^ 1.(CH2)6N4/HOAC V 丫 y _ c H o 
[ Q J (40 ^ 
23 44 
(Scheme 9) 
2-Ethynyi-4,5-diphenyloxazole (46) was prepared in two steps 
from aldehyde (44) by a method reported by Corey^^^ Thus, 2-(1',1'-
clibromoethenyl)-4,5-diphenyloxazole (45) was formed by reaction of 
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aldehyde (44) with the carbon tetrabromide-triphenylphosphine. This gem-
dibromide (45) was then converted into the corresponding terminal acetylene. 
Reaction of g^m-dibromide (45) with A7-butyllithium in THF formed the litliio 
derivative and hydrolysis of the lithium acetylide produced 2-ethynyl-4,5-
diphenyloxazole (46) (Scheme 10). 
T V C H O P h 二 Br4 • J W H ^ C B r , 
[ Q j (53 %) L y j 
44 45 
1.^ BuU/THF > H 
2.H2O ^ — 
(70 %) t y ^ 
46 
(Scheme 10) 
2-Ethyny 1-4,5 -diphenyloxazole (46) was converted to the 
corresponding cuprous salt (47) by reacting with a CUSO4-NH4OH-NH2OH 
mixture94a (Scheme 11). 
O l ( S I 
園 4 / N H 4 O � 二 
一 NH20HHC1 j^^V^^y 




5-lodovamlliii reacted with monomethyl malonate (48) to form 
olefin (49) (Scheme 12). 
COOMe 
CHO 招 r = / 
H02CCH2C02Me ‘ , / f ^ 
y ^ C5HnN/C5H5N ^ ^ 
HO OMe (77 % ) HO OMe 
49 
(Scheme 12) 
Coupling of the cuprous salt (47) and the substituted iodophenol 
(49) furnished benzofiiran94 (50) (Scheme 13). 
COOMe 
+ CsH- > 
HO OMe 
^ ^ 47 49 




F. Indole Derivative 
2-Phenylmdole (51) was prepared by the following methods. 
The first method involved heating of acetophenone phenylhydrazone in the 
presence of polyphosphoric acid (PPA), giving 2-phenylmdole (51)"5 
(Scheme 14). 
o 
if^^^^rr^^CH、, [ ( j ] EtOH/HOAc ^ ^ M e Ph 




The second method made use of phenacyldimethylsulfonium 
bromide, which was prepared by reacting phenacylbromide with 
dimethylsulfide. The sulfonium salt was converted to 2-phenylindole (51) in a 
solvent mixture of aniline and AVV-diethylanilineio?. 
Alkylation of indole (51) with methyl 8-bromooctanoate 
furnished ester (52), and saponification yielded acid (53) (Scheme 15). 




l .NaH/DMF ^ ^ ^ ^ 
52 
NaOH/MeOH ^ ^ ^ 
(90 % ) 一 
53 
(Scheme 15) 
G. Benzene Derivative 
3,4-Dihydroxybeiizaldehyde was di-alkylated with benzyl 
chloride to form di-alkylated aldehyde?] (54). Reduction of aldehyde (54) 
with NaBH4 gave di-alkylated alcohol (55). Alkylation of alcohol (55) with 
methyl 8-bromooctanoate furnished ester (56), and saponification gave acid 
(57) (Scheme 16). 
40 
H O � 八 o A 
N j ； ^ l .NaH/DMF ^ f ^ 
H O A A C H O ^ 0 - O A A C H O 
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O 
NaBHj/MeOH ^X^^^^^^。^^^：；；^ l .NaH/DMF 
~ 2 N N a O H 2. Br(CH2)7COOM^ 
( 9 7 % ) [ Q J G ( 4 5 % ) 
55 
NaOH/MeOH 
^ ^ 56 
(Scheme 16) 
3,4-Dihydroxybenzaldehyde was alkylated with a,a'-
dichlorotoluene to form alkylated aldehyde (58), which was then reduced 
with NaBH4 to fiimish alkylated alcohol (59). Alkylation of the alcohol with 
methyl 8-bromooctanoate furnished ester (60), and saponification furnished 
acid (61) (Scheme 17). 
41 
z V ^ 、 2.PhCHCl2 
‘‘ 58 
NaBH4/MeOH ^f^^^^^V^O^lf^ I.NaH/DMF 
(85 %) 外 (40 %) 





Piperonyl aldehyde was reduced with NaBH4 to form piperonyl 
alcohol (62). Alkylation of the alcohol with methyl 8-bromooctanoate 
furnished ester (63), and saponification gave acid (64) (Scheme 18). 
42 
O - ' V ^ C H O ~ 2 N N a O H 〈 。 " ^ ^ ^ ^ 。 “ 
(95 % ) 
62 
LNaH/DMF 
(63 % ) 
63 
NaOH/MeOH 广“"]^^ 
~ ( 7 1 % ) 、 ^ 
64 
(Scheme 18) 
H. Triphenylcarbinol Derivative 
The commercially available triphenylmethanol was alkylated 
with methyl 8-bromooctanoate to form ester (65), and saponification gave 
acid (66) (Scheme 19). 
o o 
/ r ^ l .NaH/DMF / p ^ 
< Q H r » 2.Br(C 響 OOM'e 
O (59%) 0 
65 
0 





IV. Results and Discussion - Pharmacological Activity* 
Octimibate analoges (20, 27, 33, 38, 43, 50, 53, 57, 61, 64, and 
66) were tested in the two IP-sensitive systems - human platelets and rat 
colon. 
Human platelet is the most sensitive preparation to IP agonists. 
0.27 r|M of cicaprost (8) completely inhibited the platelet aggregation 
induced by U46619 (600 r|M), but did not alter the shape change (Figure 4a). 
At the concentration of 2.7 r|M, cicaprost (8) abolished both the aggregation 
and shape change. Of all the novel octimibate analogs (20, 27, 33, 38, 43, 
50, 53, 57, 61, 64 and 66) tested, only analog (27) showed antiaggregatory 
effect in a dose-dependent manner (Figures 5 and 6). Its IC50 is 12.2 |iM; it is 
much higher than that of octimibate (0.21 |jM)37. All of the novel octimibate 
analogs neither had proaggregatory actions nor antagonized the inhibition of 
aggregation by cicaprost (8) (Figure 4b-d). 
V U 4 6 6 I 9 ( 6 0 0 i i M ) b U 4 6 6 1 9 ( 6 0 0 n M ) C U46619 (600 nM) d 1/46619 (600 nM) 
务 ： ‘ 寺 - I I 
I y ^ ^ 广 — 严 ； 
1 ..、— , H 
Gcaprost Pretreatcd with 
2 0.27 nM 27 5.1 jiM Pietrutea with PretreawxJ with 
K + 53 6\iM 66 5 � U M 
运 cicaprost + _ + 
一 0_27 nM cicaprost dcaorcm 
0 ^ 7 nM 0 J 7 n M 
Figure 4 : Transmission Charts of Compounds 27, 53 and 66 for the Inhibition 
of Platelet Aggregation Induced bv U46619 
* All the results are provided by Prof. Robert L. Jones (Department of 
Pharmacology). 
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Figure 5 : Trasmission Charts of Compound 27 for the Inhibitor of Platelet 
Aggregation Induced by U46619 
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Figure 6 : Dose-response Curves of Compounds 27. 53 and 66 for the 
Inhibition of Platelet Aggregation 
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Rat colon is sensitive to the inhibitory action of PGI? (6) and 
related prostanoids, which appear to be mediated via I P - r e c e p t o r i 3 5 . There is 
apparent variation between rats in terms of spontaneous activity. In order to 
choose a reliable quantitative method, two ways were compared. One is 
based on the integration of the area under the trace (Method 1); the other is 
on the average contraction force changed (Method 2). There is a good 
agreement between them (Figure 7). However, the integration method 
absolutely depends upon the precise width of selected area. Such requirement 
for the average method is relatively low，it has been therefore chosen to 
quantify spontaneous activity of rat colon. 
CM " 
100 -1 ^ 
I 
I RA2 = 0.995 
： 6 � - / 
I z 
c 40 - A 
！ 2。： 
0) 0 - y^ 
cn q X 
I ^ 
O -20 -t 1 1 1 1 ‘ 1 " 1 ‘ 1 ‘ 
-20 0 20 40 60 80 100 
Changes {%) quantified by M e t h o d 1 
Method 1: the integration of the area under trace 
Method 2: the average contraction force 
Figure 7 : Comparison of Two Quantitative Methods for the Changes of 
Spontaneous Activity of Rat Colon 
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The IC50 of cicaprost on the spontaneous activity of rat colon is 
3.8 tiM. Compounds (20，33, 38, 43, 50, 57, 61, 64 and 66) did not show 
inhibitory action on the preparation, while compounds (27, 53) attenuated the 
activity (Figure 8). However, the data should be interpreted with caution 
because the solvent control (ethanol + alkaline saline) was found to have 
inhibitory influence over the testing system. 16 [il Ethanol plus 64 fil alkaline 
saline could decrease the activity by 23.9 %. If we can further verify that the 
effects do result from the compounds themselves, it would be interesting to 
compare their differential effects between two IP-sensitive systems. Another 
point we should bear in mind is the problem of non-specificity. There is no 
guarantee that the inhibition is due to activation of IP-receptors, because of 
100 -1 
f ： ^^^ i l 扣 「 • ~ Cicaprost jL 
^ / z r z I 
O 40 - 0 ” 53 / / 
S- A I — 66 / / 
i L 
-20 H 1 1 « 1 1 1 1 1 1 1 1 
-10 - 9 -8 -7 - 6 - 5 - 4 
Log (inhibitors, M) 
I 
Figure 8 : The Dose-response Curves of Cicaprost, Compounds 11. 53 and 66 
for Inhibition of Activity of Rat Colon 
48 
V. Conclusion 
From our studies, compounds (20, 33，38, 43，50, 53，57，61， 
64, 66) have very little affinity for the IP-receptor present on the human 
platelet, while compound (27) showed antiaggregatory effect in a dose-
dependent manner. By comparing the structures of all of the novel octimibate 
analogs with that of octimbate (13) (Figure 9), we conclude that both the 1,2-
diphenyl moiety and the carboxylic acid chain of suitable length from 
diphenyl moiety are essential for the activity on IP-receptors. These results 
can be explained by fitting all the compounds into the receptor models 
(Figure 10) proposed by MeanwelP8-40 The 1,2-cliphenyl moiety which 
occupy the active sites A and B, and the carboxylic acid head which binds to 
active site D, are essential for activity on IP-receptors (e.g. Compound 27 in 
Table 5). These sites may also be occupied in compounds 50 and 57 (Table 
5)，however when fitting compound 50 into the receptor model，the methoxy 
group of compound 50 will hinder the access of the compound to the 
receptor. It is difficult for the long chain of compound 57 to form a suitable 
conformation to fit the carboxylic head into the receptor. It is strange that 
compound 53 can antagonize the activity of rat colon，because instead of site 
B, site C is occupied (Table 5). The antagonist activity of compound 53 may 
be explained by one of the following paths : i) it may act on IP-receptor to 
antagonize the action of other agonists; ii) it may act on other receptors and 
then leads to blockage at one or more points in a path of continuous 
biological processes which cause antagonist activity; or iii) it may diffuse into 
the cell and blocks one or more points in the path of continuous biological 
processes which cause antagonist activity (Figure 11). Moreover, the role of 
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Figure 9 : Comparison of the Structures of Octimibate Analogs with that of 
Octimibate 
50 
Figure 10 : Receptor Models Prosposed by Meanwell and Coworkers 
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Figure 11 : The Possible Paths for the Antagonist Activity on Rat Colon 
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VI. Further Development 
Since the results of MeanwelP8-40 show that the conformational 
restriction of the straight carboxylic acid chain by introduction of a phenyl 
ring and a double bond, would enhance the activity on IP-receptors. The 
phenyl ring on the chain would bind to the active site C by the formation of a 
c/5-double bond on the chain (Figure 10b). This idea concerning the 
conformational restriction of a straight chain has also been proposed by a 
group o f J a p a n e s e i 3 6 . They found that the carboxylic acid (67) does not show 
any activity on IP-receptors. However, when they restricted the conformation 
of the straight chain of this acid by introducing a cyclohexane ring, the 
resulting compound (68) shows activity on IP-receptors. Besides, the 
replacement of the terminal cyclohexyl group of compound (68) with a phenyl 
group or an imino moiety [a part which similar to EP 157 (13)J to form 
compounds (69) or (70), would enhance the receptor-activities. 
HOOC^^O H O O C ^ O 
(67) (68) 
0 
HOOC j H O O C ^ O 
R = HorPh R = H,Me,EtorPr 
(69) (70) 
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Hence, it is of special interest to prepare analogs having side 
chains with restricted conformation similar to PGI2 (6), iloprost (8), cicaprost 
(9), beraprost (10) and taprostene (11). 
Moreover, the receptor model proposed by Meanwell is only a 
two-dimensional one. We are not sure whether or not molecules with chiral 
carbon centers would help to fix different substituents of the molecules more 
properly to the receptor sites. It appears that compounds (68-70), with chiral 
carbon centers on the cyclohexane ring, show activity on IP-receptor. In light 
of this result, we would like also to prepare analogs with chiral carbon 
centers. 
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VIL Experimental Section 
General Methods 
Melting points were measured on a hot-stage plate and were 
uncorrected. iR NMR spectra were recorded on a Bniker WM-250 
spectrometer operating at 250 MHz or a Joel JX-60 spectrometer operating at 
60 MHz. 13C NMR spectra were recorded on a Bruker WM-250 
spectrometer operating at 62.8 MHz. H^ and i^c chemical shifts were 
reported as 5 values relative to tetramethylsilane. NMR spectroscopic terms 
were reported by using the following abbreviations : s, singlet; d, doublet; t, 
triplet; q, quartet; m, multiplet; and br, broad. Mass spectra were obtained on 
a VG 7070F mass spectrometer (EI, 70 eV). Microanalyses were performed 
at the Shanghai Institute of Organic Chemistry, Shanghai, China and at 
MEDAC Ltd, Department of Chemistry, Brunei University, Uxbridge, 
Middlesex UBS 3PH, United Kingdom. All reactions were monitored by thin-
layer chromatography (TLC) using E. Merck 0.25-mm precoated silica gel 
60-F plates. Flash chromatography was performed on E. Merck silica gel 60 
(230-400 mesh) and column chromatography was performed on E. Merck 
silica gel 60 (70-230 mesh). Tetrahydrofiiran (THF), diethylether 魄0), 
benzene, and toluene were distilled from sodium metal/benzophenone ketyl. 
Dichloromethane (CH2CI2) and diisopropylamine were distilled from calcium 
hydride. 7V,iV-Dimethyl formamide (DMF) and dimethyl sulfoxide (DMSO) 
were distilled from calcium hydride under reduced pressure (15-18 mmHg) 
and stored over type 4A (4-A) molecular sieves. Methanol was distilled from 
Mg(0Me)2. Deuteriochloroform was stored over type 4A (4-A) molecular 
sieves. All other commercially obtained reagents were used as received and 
were purchased from Aldrich, E. Merck, and Fluka chemical companies. 
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A^-Benzoyl-phenylglycine (17a)ii7 
A solution of phenylglycine (1.5 g, 10 mmol) in 10 % sodium 
hydroxide solution (25 ml) was shaked portionwise with benzoyl chloride 
(1.7 ml, 1.4 g, 10 mmol) inside a round-bottomed flask. The solid precipitated 
out was collected by suction filtration and washed with cold dichloromethane 
( 2 x 1 5 ml). It was then recrystallized from 95 % ethanol to give A^-benzoyl-
phenylglycine (17a) as a white solid (2.3 g, 92 % yield), m.p. 176-178�C 
(lit., 1 7 4 � C " 7 ) . 
2,4-Diphenyl-5(4^-oxazolone (18a)i 
A solution of TV-benzoyl-phenylglycine (17a) (2.5 g, 10 mmol) 
and A^-ethyl-A^-(Y-dimethylaiiiinopropyl) carbodiimide hydrochloride (2.1 g, 
11 mmol) in dichloromethane (40 ml) was stirred at 0 � C (ice-water bath) for 
0.5 hr. Cold dichloromethane (20 ml) was then added. The resulting solution 
was washed with water (3 x 25 ml). The organic solution was dried (MgS04) 
and concentrated to give a yellow solid which was then purified to give 2,4-
diphenyl-5(4//i-oxazolone (18a) as a white solid (2.2 g, 96 % yield), m.p. 
103-106�C (lit., 80-81118; lit., 103.5-105.5"7); iR NMR ( C D C I 3 ) : 5 7.50-
8.12 (m, lOH, Aromatic H), 4.32 (s, IH, -CH-); MS: m/z 237 (M+). 
2,4-Diphenyloxazoie-5-(8-oxyloctanoic methyl ester) (19a) 
To a suspension of sodium hydride (0.3 g，13 mmol) in NJSl-
dimethyl formamide (15 ml) was added 2,4-diphenyl-5(4//)-oxazolone (18a)( 
2.3 g, 10 mmol) under nitrogen. The resulting solution was wanned at 80 
for 15 min. After cooling to 60 methyl 8-bromooctanoate (2.6 g, 11 
mmol) in tetrahydrofiiran (15 ml) was added dropwise during 20 min. The 
solution was then stirred at this temperature for 3 hr. After cooling, it was 
poured into water (60 ml) and extracted with diethyl ether (3 x 30 ml). The 
combined ethereal extracts were washed with water (3 x 40 ml), dried 
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(MgS04) and concentrated to give a colorless oil which was purified by 
column chromatography (ethyl acetate/hexane, 1 : 9) to give 2,4-
diphenyloxazole-5-(8-oxyloctanoic methyl ester (19a) as a colorless oil (1.8 
g, 45 % yield); iH NMR ( C D C I 3 ) : 5 7.20-7.88 (m, lOH, Aromatic H), 4.15 (t, 
2H, J = 6 . 6 Hz, - O C H 2 - ) , 3.65 (s，3H, - O C H 3 ) , 2.26 (t, 2H, J 二 7.3 Hz,-
C H 2 C O - ) , 1.55 (br, 4H, Aliphatic H), 1.22 (br, 6H, Aliphatic H); " c NMR 
( C D C I 3 ) : 5 24.60, 25.29, 28.21, 28.47, 28.71, 33.83, 51.11, 56.85，65.71, 
127.04, 127.17, 128.00, 128.28, 128.38, 128.73, 131.55, 132.62, 133.78, 
136.82, 166.43, 170.90, 173.81; ； MS: m/z 394 (MH+), 393 (M+). Anal, 
calcd. for C24H27NO4, C : 73.26, H : 6.92; found C : 73.13, H: 6.44. 
2,4-Diphenyloxazole-5-(8-oxyloctanoic acid) (20a) 
A solution of 2,4-diphenyloxazole-5-(8-oxyloctanoic methyl 
ester) (19a) (1.0 g, 2.5 mmol) and sodium hydroxide (0.1 g, 2.5 mmol) in 
methanol (20 ml) was stirred at 5 0 � C for 5 hr. After cooling, the solution was 
acidified with 10 % hydrochloric acid and extracted with diethyl ether (3 x 30 
ml). The combined ethereal extracts were dried and concentrated to give a 
white solid which was then recrystallized from 95 % ethanol to give a white 
crystalline solid of (20a) (0.8 g，83 % yield)，m.p. 172-174 MS: m/z 379 
(M+). The acid was used in bioassays without fiirther purifications. 
TV-Benzoyl-valine (17b)"9 
A solution of valine (1.2 g, 10 mmol) in 10 % sodium hydroxide 
solution (25 ml) was shaked portionwise with benzoyl chloride (1.7 ml, 1.4 g， 
10 mmol) inside a round-bottomed flask. The solid precipitated out was 
collected by suction filtration and washed with cold dichloromethane ( 2 x 1 5 
ml). It was then recrystallized from 95 % ethanol to give TV-benzoyl-valine 
(17b) as a white solid (1.9 g, 86 % yield), m.p. 122-126�C. 
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4-Isopropyl-2-phenyl-5(4//).oxazolone(18b)48 
A solution of iV-benzoyl-valine (17b) (2.2 g，10 inmol) and N-
ethyl-A^-(y-dimethylairiinopropyl) carbodiimide hydrochloride (2.1 g，11 
mmol) in dichloromethane (40 ml) was stirred at 0 � C (ice-water bath) for 0.5 
hr. Cold dichloromethane (20 ml) was then added. The resulting solution was 
washed with water (3 x 25 ml). The organic solution was dried (MgS04) and 
concentrated to give a yellow solid which was then purified to give 4-
isopropyl-2-phenyl-5(4//)-oxazolone (18b) as a white solid (1.6 g, 79 % 
yield), m.p. 4 8 - 5 1 � C (lit., 48-50)i2o; iR NMR (CDCI3): 5 7.92-8.02 (m，2H, 
Aromatic H), 7.36-7.60 (m, 3H, Aromatic H)，4.26 (d, IH, J = 4.5 Hz, -CH-), 
2.34 (m, IH，，（CH3)2CH-), 1.12 (d, 3H, J = 6.9 Hz, (CH3)2CH-)，1.10 (d, 
3H, J = 6 . 8 Hz, (CH3)2CH-); 13C NMR ( C D C I 3 ) : 5 17.54, 18.69, 31.22, 
70.67, 126.05, 127.87, 128.70, 132.55, 161.68, 177.59; MS: m/z 203 (M+). 
4-Isopropyl-2-phenyioxazoIe-5-(8-oxyloctanoic methyl ester) (19b) 
To a suspension of sodium hydride (0.3 g, 13 mmol) in NJSl-
dimethyl fonnamide (15 ml) was added 4-isopropyl-2-phenyl-5(4//)-
oxazolone (18b) (2 g, 10 mmol) under nitrogen. The resulting solution was 
warmed at 80 for 15 min. After cooling to 60 methyl 8-
bromooctanoate (2.6 g, 11 mmol) in tetrahydrofuran (15 ml) was added 
dropwise during 20 min. The solution was then stirred at this temperature for 
4 hr. After cooling, it was poured into water (60 ml) and extracted with 
diethyl ether (3 x 30 ml). The combined ethereal extracts were washed with 
water (3 x 40 ml), dried (MgS04) and concentrated to give a colorless oil 
which was purified by column chromatography (ethyl acetate/hexane, 1 : 9) to 
give 4-isopropyl-2-phenyloxazole-5-(8-oxyloctanoic methyl ester) (19b) as a 
colorless oil (1.7 g, 48 % yield); m NMR ( C D C I 3 ) : 5 7.78-7.88 (m, 2H, 
Aromatic H), 7.38-7.52 (m, 3H, Aromatic H), 4.76 (dd, IH, Jj = 3.6 Hz, J2 = 
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4.9 Hz, (CH3)2CH-), 4.18 (td, 2H, J； = 6.7 Hz, J 广 1.9 Hz, -OCH2-)，3.65 (s， 
3H，-OCH3), 2.30 (t, 2H, J 二 7.5 Hz, -CH2CO-), 1.62 (br, 4H，Aliphatic H), 
1.32 (br, 6H, Aliphatic H), 1.00 (t, 6H，J = 5.3 Hz, (Cil3)2CH-); i3c NMR 
(CDCI3) 17.66, 18.54, 24.31, 25.22, 28.07, 28.25, 28.44, 31.00, 33.46, 
50.72, 57.38，64.75, 126.72, 127.99, 131.02, 134.02, 166.85，171.60，173.36; 
MS: m/z 360 (MH+). Anal, calcd. for C21H29NO4, C : 70.17，H : 8.13, N : 
3.90; found C : 70.24, H : 8.13, N : 3.86. 
4-lsopropyl-2-phenyloxazole-5-(8-oxyloctanoic acid) (20b) 
A solution of 4-isopropyl-2-phenyloxazole-5-(8-oxyloctaiioic 
methyl ester) (19b) (0.9 g, 2.5 mmol) and sodium hydroxide (0.1 g, 2.5 
mmol) in methanol (40 ml) was stirred at 50 °C for 5 hr. After cooling, the 
solution was acidified with 10 % hydrochloric acid and extracted with diethyl 
ether (3 x 30 ml). The combined ethereal extracts were dried and 
concentrated to give a white solid which was then recrystallized from 95 % 
ethanol to give white a crystalline solid of (20b) (0.8 g, 93 % yield), m.p. 
179-180 MS: m/z 345 (M+). The acid was used in bioassays without 
further purifications. 
2-Acetyloxy-l,2-diphenyiethanone (21)i25 
A solution of benzoin (2.1 g，10 mmol) and acetyl chloride (0.7 
g, 10 mmol) in pyridine (25 ml) was heated at 1 0 0 � C for 30 min. The hot 
solution was poured into ice-water mixture (100 ml) and stirred until all the 
solid was precipitated out. The solid was washed with water (3 x 25 ml) and 
recrystallized from 95 % ethanol to give 2-acetyloxy-1,2-diphenyl-ethanone 
(21) as white crystalline solid (1.9 g，76 % yield), m.p. 101-103�C; H^ NMR 
(CDCI3): 8 7.95-8.20 (m，2H, Aromatic H), 7.25-7.80 (m, 8H, Aromatic H), 
7.10 (s, IH，-CH-), 2.15 (s, 3H, - C O C H 3 ) . 
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2-Methyl-4,5-diphenyloxazoIe (22)67 
A solution of 2-acetyloxy-l,2-diphenylethanone (21) (2.5 g, 10 
mmol) and ammonium acetate (5.3 g, 70 mmol) in glacial acetic acid (25 ml) 
was refluxed for 1.5 hr. After cooling, the solution was poured into water 
(100 ml) and extracted with diethyl ether (3 x 75 ml). The ethereal extracts 
were washed with water (3 x 100 ml), dried with (MgS04) and concentrated 
to give a brown oil which was then purified by column chromatography (ethyl 
acetate/hexane, 1 : 9) to give 2-methyl-4,5-diphenyloxazole (22) as a 
colorless oil (1.7 g, 72 % yield), (lit., b.p. 214�C/17 mniHg^s); iR NMR 
(CDCI3): 8 7.30-7.45 (m, 4H, Aromatic H), 8 7.11-7.24 (m, 6H, Aromatic H), 
5 4.45 (s, 3H, -CH3); MS: m/z 236 (MH+), 235 (M+). 
2-Bromomethyl-4,5-diphenyloxazole (23)"o 
2-Bromomethyl-4,5-diphenyloxazole was obtained following a 
literature procedure.i09 A solution of 2-methyl-4,5-diphenyloxazole (22) (2.4 
g, 10 mmol), A^-bromosuccinimide (2.5 g, 11 mmol) and dibenzoyl peroxide 
(0.05 g) in carbon tetrachloride (50 ml) was refluxed under irradiation for 2 
hr. It was then filtered when hot to remove the suspended succinimide. 
Solvent was removed under vacuum to give a yellow oil which was purified 
by column chromatography (ethyl acetate/hexane, 1 : 12) to give 2-
bromomethyl-4,5-diphenyloxazole (23) as a pale yellow oil which on standing 
gave a pale yellow solid (2.8 g, 88 % yield), m.p. 105-108�C, (lit., 104-106 
�Ciio) ； iH NMR (CDCI3): 5 7.30-7.45 (m，4H, Aromatic H), 5 7.11-7.24 (m, 
6H, Aromatic H), 5 5.01 (s, 2H, -CH2Br); MS: m/z 314 (M+). 
2-Acetoxymethyi-4,5-dipheiiyloxazoie (24) 
A solution of 2-bromomethyl-4,5-diphenyloxazole (23) (3.1 g， 
10 mmol) and potassium acetate (1.0 g, 10 mmol) in TV^-dimethyl foraiamide 
(20 ml) was heated at 100 °C for 1 hr. After cooling, the solution was poured 
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into water (60 ml) and extracted with diethyl ether (3 x 40 ml). The combined 
ethereal extracts were washed with water (3 x 60 ml) , dried (MgS04) and 
concentrated to give a yellow oil which on standing gave a yellow solid. The 
solid was recrystallized from 95 % ethanol to give 2-acetoxymethyl-4,5-
diphenyloxazole (24) as a white solid. (2.9 g, 98 % yield), m.p. 126-128 
iH NMR (CDCI3): 5 7.30-7.45 (m, 4H, Aromatic H), 5 7.il-7.24(m, 6H, 
Aromatic H), 8 4.90 (s, 2H, -CH2OCO-), 5 2.50 (s, 3H, -COCH3-); MS: m/z 
293 (M+). Anal, calcd. for C18H15NO3, C : 73.71, H:5.15, N : 4.78; found C 
:73.71, H: 5.17’ N : 4.75. 
4,5-Diphenyl-2-hydroxymethyloxazole (25)i 10 
Method A : A solution of 2-acetoxymethyl-4,5-diphenyloxazolc (24) 
(2.9 g, 10 mmol) and potassium carbonate (6.9 g 50 mmol) in methanol (40 
ml) was refluxed for 0.5 hr. After cooling, the solution was neutralized with 5 
% hydrochloric acid solution. Methanol was removed under vacuum. The 
residue was diluted with water (30 ml) and extracted with diethyl ether (3 x 
50 ml). The combined ethereal extracts were dried (MgS04) and concentrated 
to give a viscous oil which on standing gave 4,5-diphenyl-2-
hydroxymethyloxazole (25) as a white solid. (2.4 g, 97 % yield), m.p. 110-
1 1 2 � C (lit., 151-156�C/< 0.1 mmHgiiO)； iR NMR ( C D C I 3 ) : 8 7.30-7.45 ( m ， 
4H, Aromatic H), 5 7.11-7.24 (m, 6 H , Aromatic H), 5 4.56 (s, 2H, - C H 2 O H ) ; 
MS: m/z 251 (M+). Anal, calcd. for C16H13NO2, C : 76.48, H : 5.21, N : 5.57; 
found C : 76.49, H: 5.21, N: 5.52. 
Method Biio : A solution of silver nitrate (2.8 g，10 mmol) in water (30 
ml) was added to a swirled solution of 2-bromomethyl-4,5-diphenyloxazole 
(23) (3.1 g, 10 mmol) in 95 % ethanol (10 ml). The resulting mixture was then 
refluxed for 1.5 hr. After filtration, the filtrate was concentrated. The residue 
was dissolved in ether (40 ml). The ethereal solution was washed with water 
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(3 X 30 ml), dried (MgS04) and concentrated to give a yellow oil. It was then 
purified by chromatography (ethyl acetate/hexanes, 1 : 2) to give a colorless 
oil which on standing gave 4,5-diphenyl-2-hydroxymethyloxazole (25) as a 
white solid. (1.6 g, 62 % yield), m.p. 1 1 0 - 1 1 3 � C (lit., 151-156 °C/< 0.1 
m m H g i i O )； iH NMR (CDCI3): 5 7.30-7.45 (m, 4H, Aromatic H), 5 7.11-7.24 
(m, 6H, Aromatic H), 5 4.56 (s, 2H, -CH2OH); MS: m/z 251 (M+). 
4,5-Diphenyi-oxazoie-2-methyl-(8-oxyloctanoic methyl ester) (26) 
To a suspension of sodium hydride (0.3 g, 13 mmol) in 即-
dimethyl formamide (10 ml) was added 2-hydroxymethyl-3,4-diphenyl-
oxazole (25) (2.5 g, 10 mmol) under nitrogen. The resulting solution was 
warmed at 80 °C for 15 min. After cooling to 60 °C，methyl 8-
bromooctanoate (2.6 g, 11 mmol) in tetrahydrofuran (10 ml) was added 
drop wise during 20 min. The solution was then stirred at this temperature for 
4 hr. After cooling, it was poured into water (50 ml) and extracted with 
diethyl ether (3 x 25 ml). The combined ethereal extracts were washed with 
water (3 x 50 ml)，dried (MgS04) and concentrated to give a colorless oil 
which was purified by column chromatography (ethyl acetate/liexane, 1 : 9) to 
give 4,5-diphenyl-oxazole-2-methyl-(8-oxyloctanoic methyl ester) (26) as a 
colorless oil (1.9 g, 47 % yield); iH NMR (CDCI3): 5 7.58-7.70 (m，4H, 
Aromatic H), 7.28-7.44 (m, 6H，Aromatic H), 4.66 (s, 2H, -CH2O-), 3.66 (s, 
3H, -OCH3), 3.62 (t, 2H; J = 6.6 Hz, -OCH2CH2-), 2.28 (t, 2H; J = 7.5 Hz,-
CH2CO-), 1.62 (br，4H, Aliphatic H), 1.34 (br, 6H, Aliphatic H); i^ C NMR 
(CDCI3) : 5 24.74, 25.72, 28.87, 28.91, 29.37, 33.91, 51.15, 64.75, 71.26, 
126.64, 127.87, 128.01, 128.40，128.50, 128.78, 132.25，132.27, 146.17, 
159.66, 173.92; MS : m/z 407 (M+). Anal, calcd. for C25H29NO4, C : 73.69, 
H : 7.17, N : 3.44; found C : 73.54, H : 7.27, N : 3.28. 
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4,5-Diphenyl-oxazoIe-2-methyI-(8-oxyloctanoic acid) (27) 
A solution of 4,5-diphenyl-oxazole-2-methyl-(8-oxyloctanoic 
methyl ester) (26) (4.0 g, 10 mmol) and sodium hydroxide (0.4 g, 10 mmol) in 
methanol (25 ml) was stirred at 50 °C for 5 hr. After cooling, the solution was 
acidified with 10 % hydrochloric acid and extracted with diethyl ether (3 x 
25 ml). The combined ethereal extracts were dried (MgS04) and concentrated 
to give a white solid which was then recrystallized from 95 % ethanol to give 
a white crystalline solid of (27) (3.4 g, 87 % yield), m.p. 178-180�C; iR 
NMR (CDCI3): 5 10.20 (br, IH, -COOH), 7.44-7.58 (m, 4H, Aromatic H), 
7.12-7.30 (m, 6H, Aromatic H), 4.56 (s, 2H, -CH2O-), 3.52 (t, 2H; J 二 6.6 
Hz，-OCH2CH2-), 2.22 (t, 2H; J = 7.5 Hz, -CH2CO-), 1.50 (br, 4H, Aliphatic 
H), 1.24 (br, 6H, Aliphatic H); i3c NMR (CDCI3) : 5 24.54, 25.71, 28.86, 
29.36, 33.92，64.63，71.30, 126.65, 127.90, 128.11, 128.44, 128.53, 132.05， 
135.10, 146.25, 159.87, 178.90; MS: m/z 393 (M+). Anal, calcd. for 
C24H27NO4, C : 73.26, H : 6.92, N : 3.56; found C : 73.25, H : 7.20, N : 3.29. 
The acid was used in bioassays without further purifications. 
2-[4-(Methyl)phenyl] benzoxazoie (28)i26 
A mixture of 2-aniinophenol (1.1 g, 10 mmol) and /7-toluic acid 
(1.4 g, 10 mmol) in polyphosphoric acid (PPA) (40 ml) was heated at 120 °C 
for 1.5 hr. After cooling, the solution was poured into water (100 ml) and 
extracted with diethyl ether (3 x 75 ml). The ethereal extracts were washed 
with water (3 x 100 ml), dried (MgSO*) and concentrated to give a brown oil 
which was then purified by column chromatography (ethyl acetate/liexane, 1 : 
9) to give 2-[4-(methyl)phenyl]benzoxazole (28) as a white solid (1.8 g, 85 % 
yield), m.p. 1 1 6 - 1 1 7 � C (lit., 116-117�Ci26); iR NMR (CDCI3): 5 8.12-8.22 
(m，2H, Aromatic H), 7.72-7.82 (m, IH, Aromatic H), 7.52-7.62 (m，IH, 
Aromatic H), 7.30-7.40 (m, 4H, Aromatic H)，2.46 (s, 3H，-CH3); MS: m/z 
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209 (M+). Anal, calcd. for C^HnNO, C : 80.36, H : 5.30, N : 6.69; found C : 
80.42, H: 5.32, N : 6.65. 
2-[4-(Bromoinethyl)phenylJ benzoxazole (29)77b 
2-[4-(Bromomethyl)phenyl]benzoxazole (29) was obtained following 
literatures procedures. 127 a solution of 2-[4-(methyl)phenylJbenzoxazole (28) 
(2.1 g, 10 mmol), 7V-bromosuccinimide (2.5 g, 11 mmol) and dibenzoyl 
peroxide (0.05 g) in carbon tetrachloride (50 ml) was refluxed under 
irradiation for 2 hr. It was then filtered when hot to remove succinimide. 
Solvent was removed under vacuum to give a yellow oil which was purified 
by column chromatography (ethyl acetate/hexane, 1 : 12) to give 2-[4-
(bromomethyl)phenyl]benzoxazole (29) as a pale yellow solid (2.2 g, 78 % 
yield), m.p. 158-160�C, (lit., 160-165�C77b); iR NMR (CDCI3): 5 8.20-8.32 
(m, 2H, Aromatic H)，7.68-7.84 (m, 2H, Aromatic H)，7.48-7.66 (m, 2H, 
Aromatic H), 7.30-7.46 (m, 2H, Aromatic H), 4.56 (s, 2H, -CHiBr); MS: m/z 
288 (M+, 8iBr), 286 (M+, 79Br). 
2- [4-(Acetoxymethyl)phenyI] benzoxazole (30) 
A solution of 2-[4-(bromomethyl)phenyl]benzoxazole (29) (2.9 
g, 10 mmol) and potassium acetate (1.0 g, 10 mmol) in A^^-dimethyl 
formamide (20 ml) was heated at 100 °C for 1 hr. After cooling, the solution 
was poured into water (60 mL) and extracted with diethyl ether (3 x 40 ml). 
The combined ethereal extracts were washed with water (3 x 60 ml), dried 
(MgS04) and concentrated to give a yellow oil which on standing gave a 
yellow solid. The solid was recrystallized from 95 % ethanol to give 2-[4-
(acetoxymethyl)phenyljbenzoxazole (30) as a white solid. (2.5 g, 93 % yield), 
m.p. 136-137�C; iR NMR (CDCI3): 5 8.22-8.30 (m, 2H, Aromatic H), 7.76-
7.84 (m, IH，Aromatic H), 7.58-7.64 (m, IH, Aromatic H)，7.48-7.58 (m，2H, 
Aromatic H), 7.32-7.42 (m，2H, Aromatic H)，5.20 (s，2H, -OCH2-), 2.18 (s, 
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3H, - C O C H 3 ) ; MS: m/z 267 (M+). Anal, calcd. for C16H13NO3, C : 71.90, H : 
4.90, N : 5.24; found C : 71.83, H : 4.95, N : 5.17. 
2-[4-(Hydroxymethyl)phenyl]beiizoxazole (31) 
A solution of 2-[4-(acetoxymethyl)phenyl]benzoxazole (30) (2.7 
g，10 mmol) and potassium carbonate (6.9 g，50 mmol) in methanol (40 ml) 
was refluxed for 0.5 hr. After cooling, the solution was neutralized with 5 % 
hydrochloric acid solution. Methanol was removed under vacuum. The 
residue was diluted with water (30 ml) and extracted with diethyl ether (3 x 
50 ml). The combined ethereal extracts were dried (MgSO*) and concentrated 
to give a viscous oil which on standing gave 2-[4-(hydroxymethyl)phenyl]-
benzoxazole (31) as a white solid. (2.1 g，84 % yield), m.p. 173-176�C; iH 
NMR ( C D C I 3 ) : 5 8.20-8.32 (m, 2H, Aromatic H), 7.70-7.84 (m, 3 H ， 
Aromatic H), 7.44-7.64 (m, 3H, Aromatic H), 7.30-7.44 (m, 2H, Aromatic 
H), 4.80 (d，2H; J = 5.9 Hz, -CH2OH), 1.90 (t, IH, J = 5.9 Hz，-CH2OH); 
MS: m/z 225 (M+). Anal, calcd. for C14H11NO2, C : 74.65, H : 4.92, N : 6.22; 
found C : 74.70, H : 4.88, N : 6.09. 
2- [4-(Methyl)pheny 1J beiizoxazole-(8-oxyloctanoic methyl ester) (32) 
To a suspension of sodium hydride (0.3 g, 13 mmol) in NJV-
dimethyl formamide (15 ml) was added 2-[4-(hyciroxymethyl)phenyl] 
benzoxazole (31) (2.3 g, 10 mmol) under nitrogen. The resulting solution was 
warmed at 80 °C for 15 min. After cooling to 60 methyl 8-
bromooctanoate (2.6 g, 11 mmol) in tetrahydrofiiran (10 ml) was added 
dropwise through 20 min. The solution was then stirred at this temperature for 
4 hr. After cooling, it was poured into water (50 ml) and extracted with 
diethyl ether (3 x 25 ml). The combined ethereal extracts were washed with 
water (3 x 50 ml), dried (MgS04) and concentrated to give a colorless oil 
which was purified by column chromatography (ethyl acetate/hexane, 1 : 9) to 
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give 2-[4-(methyl)phenyl]benzoxazole-(8-oxyIoctanoic methyl ester) (32) as a 
colorless oil (2.1 g, 56 % yield); iH NMR (CDCI3): 8 8.18-8.30 (m, 2H, 
Aromatic H), 7.76-7.84 (m, IH, Aromatic H), 7.54-7.66 (m, IH, Aromatic 
H), 7.48-7.56 (m, 2H, Aromatic H), 7.32-7.42 (m，2H, Aromatic H), 4.60 (s, 
2H, -CH2O-), 3.68 (s，3H, -CH3), 3.52 (t，2H; J = 6.6 Hz, -OCH2CH2-), 2.30 
(t，2H; J = 7.5 Hz，.CH2CO-), 1.62 (br, 4H, Aliphatic H), 1.34 (br, 6H, 
Aliphatic H); 13C NMR (CDCI3): 5 24.92, 26.06，29.09, 29.72, 34.10, 51.30, 
70.89, 72.41, 110.55, 120.08, 124.55, 125.03, 126.46, 127.78, 130.07, 
142.37, 142.76, 150.93, 174.13; MS : m/z 381 (M+). Anal, calcd. for 
C23H27NO4, C : 72.42, H : 7.13, N : 3.67; found C : 72.50, H : 7.22，N : 3.56. 
2- |4-(Methyl)phenyl] benzoxazoIe-(8-oxyloctanoic add) (33) 
A solution of 2-[4-(methyl)phenylJbenzoxazole-(8-oxyloctanoic 
methyl ester) (32) (3.8 g, 10 mmol) and sodium hydroxide (0.4 g, 10 mmol) in 
methanol (25 ml) was stirred at 50 for 5 hr. After cooling, the solution was 
acidified with 10 % hydrochloric acid and extracted with diethyl ether (3 x 
25 ml). The combined ethereal extracts were dried (MgS04) and concentrated 
to give a white solid which was then recrystallized from 95 % ethanol to give 
a white crystalline solid of (33) (3.2 g, 88 % yield), m.p. 187-189�C; MS: 
m/z 367 (M+). The acid was used in bioassays without further purifications. 
Benzoyl hydrazide (34)i2i 
To a solution of benzoyl chloride (12 ml, 0.1 mol) in diethyl 
ether (50 ml) was added dropwise hydrazine hydrate (9.8 ml，0.2 mol). The 
resulting solution was stirred at 0 °C for 15 min. The white solid formed was 
collected by suction filtration and washed with cold diethyl ether (2 x 20 ml). 
It was then recrystallized from 95 % ethanol to give a white solid of (34) (13 
g, 96 % yield); m.p. 1 1 4 - 1 1 5 � C (lit.，m.p. 115。(：⑵). 
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l-Benzoyl-4-phenyisemicarbazide (35)i22 
A solution of benzoyl hydrazide (6.8 g，50 mmol) in acetone (40 
ml) was added to a solution of phenyl isocyanate (6.5 ml, 60 mmol) in 
acetone (40 ml). The mixture was heated to reflux for 1 hr. The solvent was 
removed under vacuum to give a pale yellow solid. It was then recrystallized 
from 95 % ethanol to give a white solid of (35) (10 g, 80 % yield); m.p. 216-
218 (lit., 217-218�Ci22). 
2.4-Dihydro-4,5-diphenyl-3^-l,2,4-triazol-3-one(36)i26 
A solution of 1 -beiizoyl-4-phenylseimcarbazide (35) (1.3 g, 5 
mmol) in 2N sodium hydroxide (25 ml) was heated to reflux for 17 hr. The 
solution was filtered when hot. The filtrate was cooled and acidified with 2N 
hydrochloric acid. The white solid precipitated out was collected by suction 
filtration. It was then recrystallized from 95 % ethanol to give a white solid of 
(36) (0.7 g, 63 % yield), m.p. 255-258�C (lit., 254-256。(：⑵)；iR NMR (d -^
DMSO): 5 7.92-8.02 (m, 2H, Aromatic H), 7.20-7.70 (m, 8H, Aromatic H); 
13C NMR (d^-DMSO) : 5 127.10, 127.55, 128.39, 129.21, 129.70, 130.87, 
132.65，133.77, 145.38, 154.61, 167.29; MS: m/z 237 (M+). 
4.5-Dipheiiyl-3//-l,2,4-triazole-3-(8-oxyloctanoic methyl ester) (37) 
To a suspension of sodium hydride (39 mg, 1.3 mmol) in NJV-
dimethyl fonnamide (2 ml) was added a solution of 2,4-dihydro-4,5-diphenyl-
3//-1,2,4-triazoI-3-one (36) (237 mg, 1.0 mmol) in //^-dimethyl fonnamide 
(4 ml). The mixture was heated at 1 0 0 � C under nitrogen for 15 min. It was 
then cooled to 6 0 � C . A solution of methyl 8-bromooctanoate (261 mg，1.1 
mmol) in jV^-dimethyl fonnamide (2 ml) was added dropwise to the above 
mixture. The resulting solution was heated at 60 for 4 hr. After cooling, 
the solution was poured into water (50 ml) and extracted with diethyl ether (3 
X 20 ml). The combined ethereal extracts were washed with water (2 x 25 
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ml)，dried (MgSOj) and concentrated to give a white solid which was purified 
by column chromatography (ethyl acetate/hexane, 2 : 3) to give a white solid 
of (37) (147 mg, 37 % yield), m.p. 190-192�C; iH NMR ( C D C I 3 ) : 5 7.20-
7.50 (m，10 H, Aromatic H), 3.92 (t, 2H, J = 11 Hz, -OCH2-), 3.66 (s, 3H,-
O C U 3 ) , 2.30 (t, 2H，J = 7.5 Hz, -CH2CO-), 1.88 (m, 2H, Alphatic H)，1.64 
(m, 2H, Aliphatic H), 1.38 (br, 6H, Aliphatic H); 13C NMR (CDCI3): 5 24.69, 
26.48, 28.63，28.80，28.99, 34.07, 45.74, 51.30, 127.03, 127.25, 127.87, 
128.46, 129.35, 129.82, 134.11, 144.31，153.46, 174.10; MS: m/z 393 (M+). 
Anal, calcd. for C23H27N3O3, C : 69.64, H : 6.64, N : 11.07; found C : 69.87， 
H : 6.84, N : 10.95. 
4,5-Diphenyl-3Ar-l,2,4-triazole-3-(8-oxyloctanoic add) (38) 
A solution of 4,5-diphenyl-3//-1,2,4-triazole-3-(8-oxyloctanoic 
methyl ester) (393 mg，1 mmol) and sodium hydroxide (40 mg, 1 mmol) in 
methanol (10 ml) was stirred at 50 °C for 3 hr. After cooling, the solution was 
acidified with 10 % hydrochloride acid and extracted with diethyl ether (3 x 
25 ml). The combined ethereal extracts were dried (MgS04) and concentrated 
to give a white solid which was then recrystallized from 95 % ethanol to give 
a white crystalline solid of (38) (339 mg, 89 % yield), m.p. 196-198 MS: 
m/z 379 (M+). The acid was used in bioassays without further purifications. 
3,4-Diphenylfuran (39)9o 
4-Phenyloxazole (1.5 g, 10 mmol), diphenylacetylene (1.8 g, 10 
mmol) and triethylamine (0.2 ml) was heated at 2 8 0 � C in a sealed-tube for 2 
d. 3,4-Diphenylfuran formed was collected by vacuum distillation (60-65 
�C/1.5 mmHg) and it was then purified by column chromatography (ethyl 
acetate/hexane, 1 : 2) to give a colorless oil which on standing gave a white 
solid of (39) (1.6 g, 71 % yield), m.p. 109-111 (lit., 109-110 C^^ o)； iH 
68 
NMR (CDCI3): 8 7.58 (s, 2H, Furan H), 7.20-7.32 (m, 10 H, Aromatic H); 
MS: m/z 220 (M+). 
3,4-Diphenyl-2-furaldehyde (40)129 
A solution of dichloromethyl methyl ether (0.1 ml, 1.2 mmol) 
and 3,4-diphenylfiiraii (39) (218 mg, 1.0 mmol) in dichloromethane (4 ml) 
was cooled to - 7 8 � C . Titanium (IV) chloride (0.1 ml, 1.0 mmol) was then 
added. The resulting solution was stirred at - 7 8 � C for 2 hr. The solution was 
quenched with water (12 ml) and extracted with diethyl ether ( 3 x 1 0 ml). The 
combined ethereal extracts were dried (MgSOj) and concentrated to give an 
orange solid which was then purified by column chromatography (ethyl 
acetate/hexane, 1 : 6) to give a white solid of (40) (213 mg, 86 % yield), 124-
1 2 5 � C ; iH NMR (CDCI3): 5 9.58 (s, IH, -CHO), 7.82 (s, IH, Furan H), 
7.08-7.48 (m, lOH，Aromatic H); ^^ C NMR (CDCI3) : 5 127.79，128.37, 
128.57, 128.81, 129.37, 130.03, 130.14, 137.26, 144.34, 149.08, 177.90; 
MS: m/z 248 (M+). 
2-Hydroxymethyl-3,4-diphenylfuran (41)i30 
A solution of 3,4-diphenyl-2-furaldehyde (40) (49 mg，0.2 
mmol), sodium borohydride (2.8 g, 0.07 mmol) and 2N sodium hydroxide (2 
drops) in methanol (1 ml) was stirred at 2 5 � C for 15 min. The solution was 
quenched with 2N sulfuric acid (0.2 ml) and mixed with a water-ether mixture 
(1:1, 20ml). The aqueous solution was extracted with diethyl ether (2 x 10 
ml). The combined ethereal extracts were dried (MgS04) and concentrated to 
give a yellow liquid which was then purified by column chromatography 
(ethyl acetate/hexane, 1 : 1) to give a colorless oil of (41) (47 mg, 95 % 
yield); IH NMR (CDCI3): 5 7.54 (s, IH, Furan H)，7.08-7.36 (m, lOH, 
Aromatic H)，4.60 (s, 2H, -CH2OH), 2.44 (br, IH，-CH2OH); MS: m/z 250 
(M+). 
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3,4-Diphenylfuraii-2-methyl-(8-oxyloctaiioic methyl ester) (42) 
To a suspension of sodium hydride (0.3 g, 13 mmol) in NJ^-
dimethyl formamide (10 ml) was added with 2-hydroxymethyl-3,4-
diphenylfiiran (41) (2.5 g, 10 mmol) under nitrogen. The resulting solution 
was wanned at 8 0 � C for 15 min. After cooling to 6 0 � C , methyl 8-
bromooctanoate (2.6 g, 11 mmol) in tetrahydrofiiran (10 ml) was added 
dropwise during 20 min. The solution was then stirred at this temperature for 
4 hr. After cooling, it was poured into water (50 mL) and extracted with 
diethyl ether (3 x 25 ml). The combined ethereal extracts were washed with 
water (3 x 50 ml), dried (MgS04) and concentrated to give a colorless oil 
which was purified by column chromatography (ethyl acetate/hexane, 1 : 9) to 
give 3,4-diphenylfiiran-2-methyl-(8-oxyloctanoic methyl ester) (42) as a 
colorless oil (2.0 g, 49 % yield); H^ NMR (CDCI3): 5 7.58 (s，IH, Furan H), 
7.12-7.38 (m, lOH, Aromatic H), 4.42 (s, 2H, -CH2O-), 3.66 (s, 3H, -OCH3), 
3.48 (t, 2H; J = 6.6 Hz, -OCH2CH2-), 2.30 (t, 2H; J = 7.6 Hz, -CH2CO-), 
1.62 (br, 4H, Aliphatic H)，1.32 (br，6H, Aliphatic H); i^c NMR (CDCI3): 8 
24.87, 29.01, 34.07, 51.31, 128.32, 128.64，128.91, 129.40, 129.97, 131.09; 
MS : m/z 406 (M+). Anal, calcd. for C26H30O4, C : 76.82, H : 7.44; found C : 
76.90，H : 7.50. 
3,4-Diphenylfuran-2-methyl-(8-oxyloctanoic acid) (43) 
A solution of 3,4-diphenylfuran-2-methyl-(8-oxyloctanoic methyl 
ester) (42) (4.1 g, 10 mmol) and sodium hydroxide (0.4 g, 10 mmol) in 
methanol (25 ml) was stirred at 5 0 � C for 5 hr. After cooling, the solution was 
acidified with 10 % hydrochloric acid and extracted with diethyl ether (3 x 
25 ml). The combined ethereal extracts were dried (MgS04) and concentrated 
to give a white solid which was then recrystallized from 95 % ethanol to give 
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a white crystalline solid of (43) (3.4 g，86 % yield), m.p. 171-174�C; MS: 
m/z 392 (M+). The acid was used in bioassays without further purifications. 
4,5-Diphenyloxazole-2-carboxaldehyde (44) 
Method A : A solution of oxalyl chloride (1 ml, 11 mmol) in 
dichloromethane (25 ml) was placed in a two-neck round-bottomed flask 
fitted with two dropping ftinnels. Solutions of dimethyl sulfoxide (1.7 ml, 22 
mmol) in dichloromethane (5 ml) and 4,5-diphenyl-2-hydroxymethyloxazole 
(25) (2.5 g, 10 mmol) in dichloromethane (10 ml) were placed into two 
funnels separately. The flask was cooled to -50 °C to - 6 0 � C and the solution 
was stirred for 5 min. The dimethyl sulfoxide solution was added and the 
mixture was stirred for 15 min. The alcohol solution was then added during 
10 min. and continued to stirred for 15 min. EtgN was then added and stirred 
for a fiirther 5 min. The temperature of the reaction was then allowed to warm 
to room temperature. The solution was poured into water (100 ml) and 
extracted with dichloromethane (3 x 50 ml). The combined organic extracts 
were washed with water (3 x 100 ml), dried (MgS04) and concentrated to 
give a colorless oil which was purified by column chromatography (ethyl 
acetate/hexane, 1 : 10) to give 4,5-diphenyloxazole-2-carboxaldehyde (44) as 
colorless oil (2.3 g, 92 % yield); iH NMR (CDCI3): 5 7.30-7.45 (m，4H, 
Aromatic H)，5 7.11-7.24 (m, 6H, Aromatic H), 5 11.34 (s，IH, -CHO); MS: 
m/z 249 (M+). Anal, calcd. for C16H11NO2, C : 77.10, H : 4.45, N : 5.62; 
found C : 77.06, H : 4.47, N : 5.61. 
Method B : 4,5-Diphenyloxazole-2-carboxaldehyde (44) was also 
synthesized from 2-bromomethyl-4,5-diphenyloxazole (23) under Sommelet 
conditions as follows : A solution of 2-bromomethyl-4,5-diphenyloxazole 
(23) (3.1 g, 10 mmol) and hexamethylenetetraamine (2.8 g, 20 mmol) in 
acetic acid (15 ml) was heated to reflux for 3 hr. Hydrochloric acid (5 ml) 
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was then added to the solution and continued to stir for a further 0.5 hr. After 
cooling, the solution was poured into water (100 ml) and extracted with 
diethyl ether (3 x 50 ml). The combined ethereal extracts were washed with 
water (50 ml), 10 % Na^COg (50 ml) and water (50 ml). The ethereal extracts 
were dried (MgS04) and concentrated to give a colorless oil which was 
purified by column chromatography (ethyl acetate/hexane, 1 : 10) to give 4,5-
diphenyloxazole-2-carboxaldehyde (44) as a colorless oil (1.0 g, 40 % yield). 
2-( r，1 '-Dibromoethenyl)-4,5-diphenyloxazoIe (45) 
A solution of carbon tetrabromide (3.8 g, 11 mmol) and 
triphenylphosphine (5.9 g, 23 mmol) in dichloromethane (40 ml) was stirred 
at 0 � C for 5 min to give a brown solution. 4,5-Diphenyloxazole-2-
carboxaldehyde (44) (1.4 g, 5.7 mmol) in dichloromethane (5 ml) was added 
to the above solution and continued to stir for a further 5 min. The solution 
was allowed to room temperature. Hexane (50 ml) was added to the solution 
and the solid precipitated out was discarded. The filtrate was concentrated to 
give a yellow viscous oil which was purified by column chromatography 
(ethyl acetate/hexane, 1 : 14) to give a colorless oil of (45) (2.1 g, 53 % 
yield); iH NMR (CDCI3): 5 7.30-7.45 (m, 4H, Aromatic H)，5 7.11-7.24 (m, 
6H, Aromatic H); MS: m/z 407 (M+, ^iBr-Sifir), 405 (M+, 79Br-8iBr), 403 
(M+, 79Br-79Br). Anal, calcd for CiiHuNOBr】，C : 50.14, H : 2.74, N : 3.46; 
found C : 50.44, H : 2.77, N : 3.43. 
2-Ethynyl-4,5-diphenyloxazole (46) 
A solution of 2-( 1 1 '-dibromoethenyl)-4,5-diphenyloxazole (45) 
(2.3 g, 5.7 mmol) in tetrahydrofiiran (45 ml) was treated with «-butyllithium 
(7.1 ml, 11 mmol) at -78 The resulting solution was stirred at this 
temperature for 1 hr. It was then wanned to 25 and continued to stir for a 
further 1 hr. Water (40 ml) was added and the solution was extracted with 
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diethyl ether (3 x 30 ml). The combined ethereal extracts were dried (MgSO*) 
and concentrated to give a brown oil which was then purified by column 
chromatography (ethyl acetate/hexane, 1 : 2) to give a white solid of (46) (1.7 
g, 70 % yield), m.p. 1 3 1 - 1 3 4 � C ; iR NMR (CDCI3): 5 7.30-7.45 (m, 4H, 
Aromatic H), 5 7.11-7.24 (m，6H, Aromatic H), 3.34 (s, IH, -C CH); MS: 
m/z 245 (M+). Anal, calcd. for CnHnNO, C : 83.25, H : 4.52，N : 5.71; 
found C : 83.22, H: 4.65, N : 5.50. 
Monomethyl malonate ( 4 8 ) " 6 
A solution of malonic acid (20.8 g, 0.2 mol) and concentrated 
sulfuric acid (0.2 ml, a catalytic amount) in methanol (80 ml) was heated to 
reflux for 6 hr. After cooling, the excess acid was neutralized with sodium 
hydrogen carbonate (saturated solution). The solution was then concentrated 
under vacuum. The aqueous solution remained was extracted with diethyl 
ether (3 x 60 ml). The ethereal extracts were dried (MgS04) and concentrated 
to give dimethyl malonate as a colorless liquid (23.5 g, 89 % yield). 
A solution of potassium hydroxide (5.6 g, 0.1 mol) in methanol 
(30 ml) was added dropwise through 1.5 hr. to a solution of dimethyl 
malonate (13.2 g, 0.1 mol) in methanol (60 ml). The mixture was stirred at 25 
�C for 3 hr. A white solid was precipitated out. The solution was heated in 
order to dissolve the white solid and filtered when hot. The filtrate was 
allowed to cool. White crystalline solids formed were collected by suction 
filtration to give (48) (11.5 g, 90 %), m.p. 113-115 (lit., 114-115�C)ii6. 
Methyl 3-methoxy-4-hydroxy-5-iodocinnamate (49) 128 
A solution of S-iodovanillin (5.6 g, 20 mmol), monomethyl 
malonate (4.7 g, 40 mmol) and pyrrole (0.25 ml) in pyridine (10 ml) was 
heated to reflux for 8 hr. The solvent was removed under vacuum and the 
residue was mixed with 2N hydrochloric acid (30 ml) in ethyl acetate (50 ml). 
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The organic extract was washed with brine (2 x 10 ml) and dried (MgSOj). 
The solvent was removed under vacuum to give a brown oil. It was then 
purified by column chromatography (ethyl acetate/hexane, 2 : 3) to give a 
colorless oil which on standing gave a white solid of (49) (5.1 g，77 % yield), 
m.p. 1 1 1 - 1 1 3 � C ; iH NMR (CDCI3): 6 7.59 (d, IH, J = 15.9 H z , -
CH=CHCO-), 7.00 (d, IH, J = 6.1 Hz, Aromatic H)，6.88 (d, 1H,J=8.2 Hz, 
Aromatic H), 6.26 (d, IH, J = 15.9 Hz, -CH=CHCO-), 6.10 (s, IH, -OH), 
3 . 8 7 (s , 3 H , - O C H 3 ) , 3 . 7 6 (s , 3 H , - C O O C H 3 ) ; M S : m / z 3 3 4 ( M + ) . 
5-(2-Methoxycarbonyl-rra/i5-ethenyl)-7-methoxy-2-(4',5'-diphenyl-
oxazolyI)-benzo1 furan (50a) 
A mixture of CUSO4.5H2O (2.5 g, 10 mmol) and 28 % N H 4 O H 
(10 ml) was stirred for 5 min. under N2. After addition of water (40 ml), 
N H 2 O H HCI (1.4 g, 20 mmol) was added. After 5 min., acetylene (46) ( 2 . 5 g, 
10 mmol) in ethanol (50 ml) was added. The yellow precipitate formed was 
collected by suction filtration and washed successively with water (10 ml), 
ethanol (10 ml) and ether (10 ml). The solid was dried for 4 h at 65 °C in 
vacuo to give a yellow cuprous salt of (47) (1.9 g, 63 % yield). 
Methyl 3-methoxy-4-hydroxy-5-iodocinnamate (49) (6.7 g, 20 
mmol) and cuprous acetylide (47) (6.2g, 20 mmol) in pyridine (60 ml) were 
heated at 115 °C for 20 h. After cooling, pyridine was removed in vacuo. The 
residue was dissolved in chloroform (150 ml) and washed with water (3 x 30 
ml). The chloroform extracts were dried (MgSO*) and concentrated to give a 
brown oil which was then purified by chromatography (ethyl acetate/hexanes, 
1 ： 3) to give a white solid of (50a) (5.7 g, 63 %), m.p. 162-163 iR NMR 
( C D C I 3 ) : 5 7.60-7.72 (m，4H, Aromatic H)，7.54 (d, IH, J = 15.9 Hz, -
CH=CHCO-), 7.34-7.46 (m, 6H, Aromatic H), 7.28-7.34 (m, IH, Aromatic 
H), 6.98 (m，IH, Aromatic H), 6.30 (d，1H,J = 15.9 Hz, -CH^CHCO-), 6.18 
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(s，IH, Furan H), 3.94 (s, 3H，-OCH3), 3.80 (s, 3H, -COOCH3); MS m/z 451 
(M+). Anal, calcd. for C28H21NO5, C : 74.49, H : 4.69, N : 3.10; found C : 
74.38, H : 4.74, N : 3.06. 
5-(2-Hydroxycarbonyl-rra/i5-ethenyl)-7-methoxy-2-(4\5'-diphenyl-
oxazolyl)-beiizo[6]furaii (50) 
A solution of 5-(2-Methoxycarbonyl-/raA25-ethenyl)-7-niethoxy-
2-(4',5'-diphenyl-oxazolyl)-beiizo[6Jfuran (50a) (4.5 g, 10 mmol) and sodium 
hydroxide (0.4 g, 10 mmol) in methanol (25 ml) was stirred at 5 0 � C for 5 hr. 
After cooling, the solution was acidified with 10 % hydrochloric acid and 
extracted with diethyl ether (3 x 25 ml). The combined ethereal extracts were 
dried (MgSOj) and concentrated to give a white solid which was then 
recrystallized from 95 % ethanol to give a white crystalline solid of (50) (3.5 
g, 80 % yield), m.p. 164-166�C. MS m/z 437 (M+).The acid was used in 
bioassays without further purifications. 
2-Phenylmdole (51)124 
Method A115 : A solution of phenylhydrazine (2.2 g, 20 mmol) and 
acetophenone (2.4 g, 20 mmol) in ethanol (10 ml) and a few drop of glacial 
acetic acid was wanned at 60 °C for 15 min. The solid formed was filtered by 
suction and washed with 2 % HCl (15 ml), and was followed by cold 95 % 
ethanol (2 x 15 ml). The crude phenylhydrazone (2.1 g，10 mmol) in 
polyphosphoric acid (PPA) (40 ml) was heated at 120 °C for 10 min. After 
cooling，the mixture was poured into ice-water mixture (100 ml). The solid 
precipitated out was collected and recrytallized from 95 % ethanol to give 2-
phenylindoie (51) as a white solid (2.8 g, 73 %), m.p. 187-189 (lit., 188-
189。(：：124) ； MS: m/z 193 (M+ ). 
Method B107 ： A solution of phenacyldimethylsulfonium bromide (5.2 g, 
20 mmol) and aniline (60 mmol) in A^V-diethylanilme (20 ml) was refluxed 
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for 4 hr. After cooling, the solution was quenched in ice-cold 2N HCl (40 ml) 
and extracted with ether (3 x 50 ml). The combined ethereal extracts were 
washed with dilute HCl (40 ml) and water (40 ml), dried (MlgS04) and 
concentrated to give 2-phenylindole (51) (3.3 g, 85 % yield), m.p. 1 8 6 � C 
(lit., 186-188�C124) It was used in the following experiment without further 
purification. 
2-PhenylmdoIe-l-(8-octanoic methyl ester) (52) 
To a suspension of sodium hydride (0.3 g，13 mmol) in NJV-
dimethyl fonnamide (15 ml) was added with 2-phenylindole (51) (1.9 g, 10 
mmol). The resulting mixture was heated at 100 for 15 min. After cooling 
to 60 a solution of methyl 8-bromooctanoate (2.6 g, 11 mmol) in 
tetrahydrofuran (15 ml) was added dropwise. The solution was then heated at 
6 0 � C for 2 hr. After cooling, the solution was poured into water (60 ml) and 
extracted with diethyl ether (3 x 30 ml). The combined ethereal extracts were 
washed with water (2 x 40 ml), dried (MgS04) and concentrated to give a 
yellow oil, which was then purified by chromatography (ethyl acetate/hexane, 
1 : 8) to give a colorless oil of (52) (2.7 g, 76 % yield); iH NMR (CDCI3): 5 
7.58-7.66 (m，IH, Aromatic H), 7.32-7.52 (m, 6H, Aromatic H), 7.06-7.26 
(m, 2H, Aromatic H), 6.50 (s，IH, -CH=), 4.12 (t, 2H; J = 7.6 Hz, -NCH2-), 
3.64 (s，3H, -OCH3), 2.22 (t, 2H; J = 7.5 Hz，-CH2CO-), 1.66 (br, 2H, 
Aliphatic H), 1.50 (br, 2H, Aliphatic H), 1.14 (br, 6H, Aliphatic H); ^^ C 
NMR (CDCI3) : 5 24.71，26.46, 28.59，28.82，29.74，33.92, 43.82, 51.24， 
102.17, 109.95，119.69, 120.55, 121.45, 127.83，128.40, 129.41, 133.40, 
137.46, 141.29, 173.93; MS: m/z 349 (M+). Anal, calcd. for C23H27NO2, C : 
79.05, H : 7.79, N : 4.01; found C : 79.04，H : 7.77, N : 3.92. 
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2-Phenylindole-l-(8-octanoic acid) (53) 
A solution of 2-phenylmdole-1 -(8-oxyloctanoic methyl ester) 
(52) (3.5 g, 10 mmol) and sodium hydroxide (0.4 g, 10 mmol) in methanol 
(25 ml) was stirred at 50 for 5 hr. After cooling, the solution was acidified 
with 10 % hydrochloric acid and extracted with diethyl ether (3 x 25 ml). The 
combined ethereal extracts were dried (MgSO*) and concentrated to give a 
white solid which was then recrystallized from 95 % ethanol to give a white 
crystalline solid of (53) (3 g, 90 % yield), m.p. 1 5 1 - 1 5 2 � C ; iR NMR 
( C D C I 3 ) : 5 7.00-7.60 (m, 9H, Aromatic H), 6.46 (s, IH, -CH=), 4.06 (t, 2H; J 
= 7 . 6 Hz, - N C H 2 - ) , 2.20 (t, 2H; J = 7.5 Hz, -CH2CO-), 1.58 (br, 2H, 
Aliphatic H), 1.42 (br, 2H, Aliphatic H), 1.04 (br, 6H, Aliphatic H); i3c 
NMR ( C D C I 3 ) : 5 24.48，26.48，28.60, 28.77，29.75, 33.86, 43.85, 102.24, 
109.99, 119.70, 120.61, 121.52, 127.89, 128.44, 129.47, 133.47, 137.52, 
141.35, 173.51; MS: m/z 335 (M+). The acid was used in bioassays without 
further purifications. 
3,4-DibeiizyIoxybenzaldehyde (54)" 1 
To a suspension of sodium hydride (0.5 g, 20 mmol) in NJ^-
dimethyl foraiamide (10 ml) was added with 3,4-dihydroxybenzaldehyde 
(1.4 g, 10 mmol) under nitrogen. The resulting solution was wanned at 80 °C 
for 15 min. After cooling to 6 0 � C , benzyl bromide (3.4 g，20 mmol) in 
tetrahydrofuran (10 ml) was added dropwise during 20 min. The solution was 
then stirred at this temperature for 4 hr. After cooling, it was poured into 
water (50 ml) and extracted with diethyl ether (3 x 25 ml). The combined 
ethereal extracts were washed with water (3 x 50 ml), dried (MgS04) and 
concentrated to give a colorless oil which was purified by column 
chromatography (ethyl acetate/hexane, 1 : 9) to give 3,4-dibenzyloxy-
benzaldehyde (54) as a white solid (2.8 g, 89 % yield), m.p. 9 0 - 9 1 � C (lit.， 
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90-92 iH NMR (CDCI3): 6 9.80 (s，IH, CHO), 7.28-7.54 (m，12H， 
Aromatic H), 6.96-7.06 (d, IH, Aromatic H), 5.26 (s, 2H, PhCHzO-), 5.20 (s, 
2H, PhCH20-); 13C NMR (CDCI3): 5 71.09, 71.30, 113.20, 113.59, 126.40， 
127.35, 127.99, 128.08, 128.55, 128.61, 130.62, 136.39, 136.71，149.47， 
154.50, 190.52; MS: m/z 318 (M+). 
3，4-Dibenzyloxybenzyl alcohol (55)1^2 
A solution of 3,4-dibenzyloxybenzaldehyde (54) (3.2 g, 10 
mmol), sodium borohydride (0.2 g, 5 mmol) and 2N sodium hydroxide (0.2 
ml) in methanol (10 ml) was stirred at 2 5 � C for 15 min. The solution was 
quenched with 2N sulfiiric acid (5 mJ) and mixed with water-ether mixture 
(1:1, 40 ml). The aqueous solution was extracted with diethyl ether (2 x 20 
ml). The combined ethereal extracts were dried (MgS04) and concentrated to 
give a yellow liquid which was then purified by column chromatography 
(ethyl acetate/hexane, 1 : 1) to give a white solid of (55). The alcohol was 
then recrystallized from ethyl acetate-hexane (1 : 1) to give white needles of 
(55) (3.1 g, 97 0/0 yield), m.p. 70-72 (lit., 70�Ci32); iH NMR (CDCI3): 5 
7.22-7.50 (m, lOH), 6.80-7.04 (m, 3H)，5.18 (s, 2H), 5.16 (s, 2H), 4.58 (d， 
2H; J =52 Hz), 1.60 (t, IH; J = 5.2 Hz); MS: m/z 320 (M+). 
3,4-Dibeiizoxylbeiizyl-(8-oxyloctanoic methyl ester) (56) 
To a suspension of sodium hydride (0.3 g, 13 mmol) in NJS/-
dimethyl formamide (15 ml) was added 3,4-dibenzoxylbeiizy 1 alcohol (55) 
(3.20 g, 10 mmol) under nitrogen. The resulting solution was warmed at 80 ° 
C for 15 min. After cooling to 60 °C，methyl 8-bromooctanoate (2.6 g, 11 
mmol) in tetrahydrofuran (10 ml) was added dropwise during 20 min. The 
solution was then stirred at this temperature for 4 hr. After cooling, it was 
poured into water (50 mL) and extracted with diethyl ether (3 x 25 ml). The 
combined ethereal extracts were washed with water (3 x 50 ml), dried 
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(MgS04) and concentrated to give a colorless oil which was purified by 
column chromatography (ethyl acetate/hexane, 1 : 8) to give 3,4-
dibenzoxylbenzyI-(8-oxyloctanoic methyl ester) (56) as a colorless oil (2.1 g, 
45 % yield); iR NMR (CDCI3) : 6 7.22-7.50 (m, lOH, Aromatic H), 6.78-
7.00 (m, 3H, Aromatic H), 5.18 (s, 2H, PhCHsO-)，5.16 (s, 2H, PhCHsO-)， 
4 . 3 8 ( s , 2 H , - A r C H 2 0 - ) , 3 . 6 4 (s , 3 H , - O C H 3 ) , 3 . 4 0 (t, 2 H ; J = 6 . 6 H z , -
CH2O-), 2.30 (t，2H; J = 7.5 Hz, -CH2CO-), 1.60 (br, 4H, Aliphatic H), 1.30 
(br, 6H, Aliphatic H); i3c NMR (CDCI3): 8 ; MS m/z 476 (M+). Anal, calcd. 
for C30H36O5, C : 75.60，H : 7.61; found C : 75.44, H : 7.48. 
3,4-Dibenzoxyibeiizyl-(8-oxyloctanoic acid) (57) 
A solution of 3,4-dibenzoxylbenzyl-(8-octanoic methyl ester) 
(56) (4.8 g, 10 mmol) and sodium hydroxide (0.4 g, 10 mmol) in methanol 
(30 ml) was stirred at 50 °C for 4 hr. After cooling, the solution was acidified 
with 10 0/0 hydrochloric acid and extracted with diethyl ether (3 x 25 ml). The 
combined ethereal extracts were dried (MgS04) and concentrated to give a 
white solid which was then recrystallized from 95 % ethanol to give a white 
crystalline solid of (57) (3.7 g, 81 % yield), 161-162�C; MS: m/z 462 (M+). 
The acid was used in bioassays without further purifications. 
2-Phenyl-1,3-beiizodioxole-5-ca rboxaldehyde (58) 13 3 
A suspension of sodium hydride (0.5 g，20 mmol) in NJN-
dimethyl formamide (10 ml) was added with 3,4-dihydroxybeiizaldehyde 
(1.4 g, 10 mmol) under nitrogen. The resulting solution was warmed at 80 °C 
for 15 min. After cooling to 60 a,a-dichlorotoluene (1.6 g, 10 mmol) in 
tetrahydrofiiran (10 ml) was added dropwise during 20 min. The solution was 
then stirred at this temperature for 4 hr. After cooling, it was poured into 
water (50 ml) and extracted with diethyl ether (3 x 25 ml). The combined 
ethereal extracts were washed with water (3 x 50 ml)，dried (MgS04) and 
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concentrated to give a colorless oil which was purified by column 
chromatography (ethyl acetate/hexane, 1 : 10) to give 2-phenyM,3-
beiizodioxole-5-carboxaldehyde (58) as a colorless oil (1.8 g, 80 % yield); iR 
NMR (CDCI3): 5 9.80 (s, IH, -CHO), 7.26-7.64 (m, 7H, Aromatic H), 7.08 
(s, IH, -CH-), 6.86-6.98 (d, IH, Aromatic H); 13C NMR (CDCI3): 5 107.52， 
108.79, 112.05, 126.75, 128.87, 129.29, 131.08, 132.61, 135.99, 149.39’ 
153.60, 190.51; MS: m/z 226 (M+). 
2-Phenyl-l,3-beiizodioxole-5-methanoI (59)1^4 
A solution of 2-phenyl-1,3-benzodioxole-5-carboxaldehyde (58) 
(2.3 g, 10 mmol)，sodium borohydride (0.2 g, 5 mmol) and 2N sodium 
hydroxide (0.2 ml) in methanol (10 ml) was stirred at 2 5 � C for 15 min. The 
solution was quenched with 2N sulfuric acid (5 ml) and mixed with water-
ether mixture (1 : 1, 40 ml). The aqueous solution was extracted with diethyl 
ether (2 x 20 ml). The combined ethereal extracts were dried (MgS04) and 
concentrated to give a yellow liquid which was then purified by column 
chromatography (ethyl acetate/hexane, I : 1) to give a colorless oil of (59) 
(1.9 g，85 % yield); H^ NMR (CDCI3): 5 7.48-7.52 (m, 2H, Aromatic H), 
7.34-7.48 (m, 3H, Aromatic H), 6.98 (s，IH, -CH-), 6.90 (s, IH, Aromatic H), 
6.82 (s, 2H，Aromatic H), 4.58 (s, 2H，-CH2OH), 1.68 (br, IH, -CH2OH); 
MS: m/z 228 (M+). 
2-PhenyH,3-beiizodioxole-5-methyl-(8-oxyloctanoic methyl ester) (60) 
To a suspension of sodium hydride (0.3 g, 13 mmol) in NJV-
dimethyl formamide (10 ml) was added 2-phenyl-1,3-benzodioxole-5-
methanol (59) (2.3 g, 10 mmol) under nitrogen. The resulting solution was 
wanned at 80 °C for 15 min. After cooling to 60 methyl 8-
bromooctanoate (2.6 g, 11 mmol) in tetrahydrofuran (10 ml) was added 
dropwise during 20 min. The solution was then stirred at this temperature for 
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4 hrs. After cooling, it was poured into water (50 ml) and extracted with 
diethyl ether (3 x 25 ml). The combined ethereal extracts were washed with 
water (3 x 50 ml), dried (MgSOj) and concentrated to give a colorless oil 
which was purified by column chromatography (ethyl acetate/hexane, 1 ： 9) to 
give 2-phenyl-1,3-beiizodioxole-5-methyl-(8-oxyloctanoic methyl ester) (60) 
as a colorless oil (1.5 g, 40 % yield); iR NMR (CDCI3): 5 7.52-7.62 (m, 2H, 
Aromatic H), 7.42-7.50 (m，3H, Aromatic H), 6.98 (s, IH, -CH-), 6.88 (s, IH, 
Aromatic H), 6.80 (s, 2H, Aromatic H), 4.42 (s, 2H, -CH2O-), 3.68 (s，3H,-
OCU3), 3.46 (t, 2H, J = 6.6 Hz, -OCH2CH2-), 2.30 (t, 2H; J = 7.5 Hz，-
CH2CO-), 1.60 (br, 4H, Aliphatic H), 1.32 (br, 6H, Aliphatic H); 13C NMR 
(CDCI3) : 5 24.91, 26.04, 29.06, 29.71, 34.08, 51.27, 70.29, 72.81, 107.91, 
108.27’ 110.26’ 121.09, 126.36, 128.61’ 130.15, 130.58, 132.84，136.43, 
147.23, 147.97，160.96, 174.08; MS m/z 384 (M+). Anal, calcd. for 
C23H28O5, C : 71.85, H : 7.34; found C : 72.07，H : 7.24. 
2-Pheiiyl-l,3-beiizodioxoie-5-methyi-(8-oxyloctanoic acid) (61) 
A solution of 2-phenyl-1,3-beiizodioxole-5-methyl-(8-
oxyloctanoic methyl ester) (60) (3.8 g, 10 mmol) and sodium hydroxide (0.4 
g, 10 mmol) in methanol (30 ml) was stirred at 50 for 5 hr. After cooling, 
the solution was acidified with 10 % hydrochloric acid and extracted with 
diethyl ether (3 x 25 ml). The combined ethereal extracts were dried (MgS04) 
and concentrated to give a white solid which was then recrystallized from 95 
% ethanol to give a white crystalline solid of (61) (3 g, 80 % yield), m.p. 157-
159 °C; MS: m/z 370 (M+). The acid was used in bioassays without further 
purifications. 
Piperonyl alcohol (62) 
A solution of piperonal (1.5 g, 10 mmol), sodium borohydride 
(0.2 g，5 mmol) and 2N sodium hydroxide (0.2 ml) in methanol (10 ml) was 
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stirred at 25 for 15 min. The solution was quenched with 2N sulfuric acid 
(5 ml) and mixed with water-ether mixture ( 1 : 1 , 20ml). The aqueous 
solution was extracted with diethyl ether ( 2 x 1 0 ml). The combined ethereal 
extracts were dried (MgS04) and concentrated to give a white solid which 
was then purified by column chromatography (ethyl acetate/hexane, 1 : 1) to 
give a white solid of (62) (1.4 g, 95 % yield); MS: m/z 152 (M+). The iR 
NMR spectrum and m.p. are the same as an authentic sample. 
O-Piperonyl-8-octanoic methyl ester (63) 
To a suspension of sodium hydride (0.3 g, 13 mmol) in 10 mL 
A/'^-dimethyl fonnamide was added piperonyl alcohol (62) (1.5 g, 10 mmol) 
under nitrogen. The resulting solution was warmed at 80 for 15 min. After 
cooling to 60 °C, methyl 8-bromooctanoate (2.6 g, 11 mmol) in 
tetrahydrofuran (10 ml) was added dropwise during 20 min. The solution was 
then stirred at this temperature for 4 hr. After cooling, it was poured into 
water (50 ml) and extracted with diethyl ether (3 x 25 ml). The combined 
ethereal extracts were washed with water (3 x 50 ml), dried (MgS04) and 
concentrated to give a colorless oil which was purified by column 
chromatography (ethyl acetate/hexane, 1 : 9) to give O-piperonyl-8-octanoic 
methyl ester (63) as a colorless oil (1.9 g, 63 % yield); iH NMR (CDCI3): 5 
6.84 (s, IH, Aromatic H), 6.78 (s, 2H, Aromatic H), 6.95 (s, 2H, -OCH2O-), 
4.40 (s, 2H, -CH2O-), 3.68 (s, 3H, -OCH3), 3.44 (t，2H; J = 6.6 H z , -
OCH2CH2-), 2.30 (t, 2H; J = 7.5 Hz, -CH2CO-), 1.58 (br，4H, Aliphatic H)， 
1.30 (br, 6H, Aliphatic H); MS m/z 308 (M+). Anal, calcd. for C17H24O5, C : 
66.21, H : 7.84; found C : 66.56，H : 7.57. 
OPiperonyl-S-octanoic acid (64) 
A solution of O-piperonyl-8-octanoic methyl ester (63) (3.1 g, 
10 mmol) and sodium hydroxide (0.4 g, 10 mmol) in methanol (25 ml) was 
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stirred at 50 for 5 hr. After cooling, the solution was acidified with 10 % 
hydrochloric acid and extracted with diethyl ether (3 x 25 ml). The combined 
ethereal extracts were dried (MgS04) and concentrated to give a white solid 
which was then recrystallized from 95 % ethanol to give a white crystalline 
solid of (64) (2.1 g, 71 % yield), m.p. 147-151�C; MS: m/z 294 (M+). The 
acid was used in bioassays without further purifications. 
TriphenylmethyI-(8-oxyloctanoic methyl ester) (65) 
To a suspension of sodium hydride (0.3 g, 13 mmol) in NJV-
dimethyl formamide (15 ml) was added with triphenylmethanol (2.6 g, 10 
mmol). The resulting mixture was heated at 100 for 15 min. After cooling 
to 60 °C, a solution of methyl 8-bromooctanoate (2.6 g, 11 mmol) in 
tetrahydrofiiran (15 ml) was added dropwise. The solution was then heated at 
60 for 3.5 hr. After cooling, the solution was poured into water (60 ml) 
and extracted with diethyl ether (3 x 30 ml). The combined ethereal extracts 
were washed with water (2 x 40 ml), dried (MgS04) and concentrated to give 
a yellow oil, which was then purified by chromatography (ethyl 
acetate/hexane, 1 : 8) to give a colorless oil of (65) (2.5 g, 59 % yield); H^ 
NMR (CDCI3): 8 7.38-7.48 (m, 6H, Aromatic H), 7.20-7.36 (m, 9H, 
Aromatic H), 3.66 (s, 3H, -OCH3), 3.06 (t，2H; J = 6.6 Hz, -OCH2-), 2.88 (t, 
2H; J : 7.5 Hz, -CH2CO-), 1.60 (br, 4H, Aliphatic H), 1.32 (br，6H, Aliphatic 
H); 13C NMR (CDCI3) : 5 24.92, 26.11, 29.08, 30.01, 34.10, 51.29, 63.65, 
86.44, 126.79, 127.65, 128.78, 144.65, 174.13; MS: m/z 416 (M+). Anal, 
calcd. for C28H32O3, C : 80.73, H : 7.74; found C : 80.37, H : 7.97. 
Triphenylmethyl-(8-oxyloctanoic acid) (66) 
A solution of triphenylmethyl-(8-oxyloctanoic methyl ester) (65) 
(4.2 g，10 mmol) and sodium hydroxide (0.4 g, 10 mmol) in methanol (25 ml) 
was stirred at 50 °C for 5 hr. After cooling, the solution was acidified with 10 
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o/o hydrochloric acid and extracted with diethyl ether (3 x 25 ml). The 
combined ethereal extracts were dried (MgS04) and concentrated to give a 
white solid which was then recrystallized from 95 % ethanol to give a white 
crystalline solid of (66) (3.5 g, 87 % yield), m.p. 161-162�C; MS: m/z 402 
(M+). The acid was used in bioassays without further purifications. 
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